Biomarkers for dementia and mild cognitive impairment in Parkinson's disease
ABSTRACT Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well‐established risk factor for the development of dementia. However, mild cognitive impai...
Saved in:
| Published in | Movement disorders Vol. 31; no. 6; pp. 861 - 881 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Blackwell Publishing Ltd
01.06.2016
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0885-3185 1531-8257 1531-8257 |
| DOI | 10.1002/mds.26662 |
Cover
| Abstract | ABSTRACT
Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well‐established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin‐like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society |
|---|---|
| AbstractList | Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well‐established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin‐like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society. Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and of As in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. copyright 2016 International Parkinson and Movement Disorder Society Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society.Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society. ABSTRACT Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well‐established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin‐like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society |
| Author | Delgado-Alvarado, Manuel Gago, Belén Jiménez-Urbieta, Haritz Rodriguez-Oroz, María C. Navalpotro-Gomez, Irene |
| Author_xml | – sequence: 1 givenname: Manuel surname: Delgado-Alvarado fullname: Delgado-Alvarado, Manuel organization: Biodonostia Health Research Institute, San Sebastián, Spain – sequence: 2 givenname: Belén surname: Gago fullname: Gago, Belén organization: Biodonostia Health Research Institute, San Sebastián, Spain – sequence: 3 givenname: Irene surname: Navalpotro-Gomez fullname: Navalpotro-Gomez, Irene organization: Biodonostia Health Research Institute, San Sebastián, Spain – sequence: 4 givenname: Haritz surname: Jiménez-Urbieta fullname: Jiménez-Urbieta, Haritz organization: Biodonostia Health Research Institute, San Sebastián, Spain – sequence: 5 givenname: María C. surname: Rodriguez-Oroz fullname: Rodriguez-Oroz, María C. email: maria.rodriguezoroz@biodonostia.org organization: Biodonostia Health Research Institute, San Sebastián, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27193487$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU1vEzEQhi3UiqaFA38ArcQBOGzrj_jrWAItlQJEKghulteeRS67drA30P57dknCoQJxmsM8zyvNvMfoIKYICD0h-JRgTM96X06pEII-QDPCGakV5fIAzbBSvGZE8SN0XMoNxoRwIh6iIyqJZnMlZ2j5KqTe5m-QS9WmXHnoIQ7BVjb6qg-dr1z6GsMQfkAV-rUNedpXIVar0QqxpPi8VD4UsAUeocPWdgUe7-YJ-nTx5uPibb38cHm1OF_WjlNOa6Y1B9kq7LHWoGmrJRa2cZ412EvMGsXAc9E4qmSLvfPSUU0Em2vqsFRzdoJebHPXOX3fQBlMH4qDrrMR0qYYorCSZDrw_6jUjAtN8JT67B56kzY5jodMFBVaCzIFPt1Rm6YHb9Y5jP-7M_uXjsDZFnA5lZKhNS4MdggpDtmGzhBsptLMWJr5XdpovLxn7EP_xu7Sf4YO7v4Nmnevr_dGvTVCGeD2jzG2Z4RkkpvP7y_Nl8VqOV9dc7NivwBINbMA |
| CODEN | MOVDEA |
| CitedBy_id | crossref_primary_10_1016_j_nicl_2017_11_009 crossref_primary_10_1002_mds_27190 crossref_primary_10_1097_MD_0000000000030079 crossref_primary_10_2196_59649 crossref_primary_10_3389_fnagi_2022_943438 crossref_primary_10_1080_03007995_2024_2422002 crossref_primary_10_5582_bst_2024_01026 crossref_primary_10_1007_s00702_018_1935_8 crossref_primary_10_3390_bs11070094 crossref_primary_10_1002_mds_27106 crossref_primary_10_1111_ejn_16610 crossref_primary_10_3390_app14093883 crossref_primary_10_1007_s00259_025_07070_z crossref_primary_10_3389_fneur_2020_00665 crossref_primary_10_3389_fneur_2021_733570 crossref_primary_10_3389_fneur_2019_00195 crossref_primary_10_3389_fneur_2020_588140 crossref_primary_10_1016_j_neubiorev_2023_105035 crossref_primary_10_1186_s40035_017_0094_4 crossref_primary_10_2174_1874609812666190204094233 crossref_primary_10_1016_j_brainres_2024_149392 crossref_primary_10_1136_jnnp_2016_314857 crossref_primary_10_1007_s11065_023_09578_3 crossref_primary_10_1016_j_ncl_2017_01_004 crossref_primary_10_1038_s41467_024_46015_2 crossref_primary_10_1038_s41531_024_00823_x crossref_primary_10_1007_s00415_018_8755_5 crossref_primary_10_1016_j_neubiorev_2016_08_003 crossref_primary_10_1038_s41531_022_00403_x crossref_primary_10_1016_j_bj_2023_100678 crossref_primary_10_1080_00207454_2020_1860965 crossref_primary_10_1007_s00330_020_07575_1 crossref_primary_10_14336_AD_2019_1103 crossref_primary_10_1007_s00415_022_11301_w crossref_primary_10_3233_JPD_223334 crossref_primary_10_1002_hbm_24884 crossref_primary_10_1007_s00330_021_08385_9 crossref_primary_10_1002_hsr2_1514 crossref_primary_10_1002_mds_111 crossref_primary_10_1111_ejn_15899 crossref_primary_10_1038_s41598_022_07909_7 crossref_primary_10_1016_j_clinph_2022_01_136 crossref_primary_10_3389_fnagi_2019_00139 crossref_primary_10_1002_mds_27364 crossref_primary_10_1038_s41531_024_00759_2 crossref_primary_10_1111_ane_13320 crossref_primary_10_1007_s12264_017_0202_6 crossref_primary_10_1186_s41983_023_00662_2 crossref_primary_10_1002_mds_104 crossref_primary_10_1016_j_jns_2021_120015 crossref_primary_10_1016_j_neubiorev_2021_06_030 crossref_primary_10_1016_j_neurobiolaging_2022_10_001 crossref_primary_10_12677_ap_2024_143171 crossref_primary_10_3233_JPD_230154 crossref_primary_10_1016_j_nicl_2023_103548 crossref_primary_10_1016_j_jagp_2019_03_002 crossref_primary_10_1016_j_parkreldis_2023_105802 crossref_primary_10_1007_s11571_021_09671_4 crossref_primary_10_1111_jnp_12173 crossref_primary_10_1002_mds_27518 crossref_primary_10_1007_s10072_024_07729_9 crossref_primary_10_1038_s41598_023_46991_3 crossref_primary_10_1152_jn_00316_2021 crossref_primary_10_3390_ijms25073919 crossref_primary_10_1111_bpa_12730 crossref_primary_10_3389_fnagi_2022_914049 crossref_primary_10_4103_1673_5374_297091 crossref_primary_10_1002_mds_27115 crossref_primary_10_1007_s00234_020_02378_z crossref_primary_10_1002_mds_27355 crossref_primary_10_1016_j_neuro_2024_02_006 crossref_primary_10_21303_2504_5679_2018_00794 crossref_primary_10_1097_MD_0000000000034997 crossref_primary_10_1002_acn3_51429 crossref_primary_10_1016_j_ejrad_2021_109985 crossref_primary_10_3389_fnagi_2023_1124232 crossref_primary_10_1371_journal_pone_0304355 crossref_primary_10_1038_s41598_021_99167_2 crossref_primary_10_3233_JAD_201516 crossref_primary_10_1002_mds_27665 crossref_primary_10_1038_s41531_023_00602_0 crossref_primary_10_1016_j_jns_2020_117077 crossref_primary_10_1007_s00330_021_08086_3 crossref_primary_10_1159_000510325 crossref_primary_10_1007_s00415_018_8973_x crossref_primary_10_1016_j_pnpbp_2025_111272 crossref_primary_10_1007_s00774_023_01446_7 crossref_primary_10_1002_mds_27931 crossref_primary_10_1016_j_freeradbiomed_2024_04_240 crossref_primary_10_1002_mds_26968 crossref_primary_10_3389_fneur_2021_760518 crossref_primary_10_1002_mds_26683 crossref_primary_10_1016_j_nbd_2018_11_001 crossref_primary_10_1038_s41531_018_0055_3 crossref_primary_10_1016_j_ibneur_2023_10_001 crossref_primary_10_1212_WNL_0000000000209498 crossref_primary_10_1080_01616412_2023_2258038 crossref_primary_10_14336_AD_2017_0416 crossref_primary_10_1016_j_parkreldis_2020_08_010 crossref_primary_10_1111_cns_14461 crossref_primary_10_3390_medicina59101756 crossref_primary_10_3389_fneur_2020_00047 crossref_primary_10_1016_S1474_4422_19_30024_9 crossref_primary_10_3389_fnagi_2022_806026 crossref_primary_10_2174_1871527318666191114093749 crossref_primary_10_1016_j_parkreldis_2018_12_016 crossref_primary_10_1002_mds_26907 crossref_primary_10_1038_mp_2017_18 crossref_primary_10_18632_aging_103458 crossref_primary_10_1007_s11682_024_00860_3 crossref_primary_10_1016_j_parkreldis_2019_03_027 crossref_primary_10_3390_jcm12041569 crossref_primary_10_1186_s12883_021_02360_z crossref_primary_10_1155_2021_5561974 crossref_primary_10_1002_mds_27798 crossref_primary_10_1186_s13073_022_01132_9 crossref_primary_10_3233_JPD_202110 |
| Cites_doi | 10.3389/fnhum.2015.00130 10.1016/j.parkreldis.2013.03.009 10.1371/journal.pone.0073094 10.1097/RLU.0b013e3182873511 10.1016/j.neulet.2008.10.018 10.2169/internalmedicine.44.1046 10.1148/radiol.12111280 10.1097/00006231-199213100-00007 10.1002/mds.10444 10.1006/geno.2002.6707 10.1016/j.parkreldis.2015.05.020 10.1002/ana.410400309 10.1016/j.neulet.2013.12.051 10.1016/j.parkreldis.2014.08.024 10.1001/archneur.62.2.281 10.1136/jnnp-2012-304126 10.3174/ajnr.A2860 10.1001/jamaneurol.2014.2757 10.1002/mds.22227 10.1523/JNEUROSCI.0774-07.2007 10.1212/WNL.46.3.678 10.1212/WNL.0b013e3181ab2b58 10.1002/mds.20463 10.2169/internalmedicine.52.0474 10.1001/archneur.60.12.1745 10.1136/jnnp.54.9.787 10.1002/ana.20635 10.1007/s00415-012-6648-6 10.1097/WAD.0b013e31824acd84 10.1016/j.neulet.2006.12.008 10.1080/13803390903521018 10.1136/jnnp-2011-300828 10.1016/j.neuroimage.2007.09.072 10.1002/ana.10846 10.1002/mds.22007 10.1097/WNN.0b013e31817995e7 10.1212/01.WNL.0000149510.41793.50 10.2967/jnumed.111.089946 10.1016/j.parkreldis.2012.04.028 10.1016/S0140-6736(05)79387-9 10.1093/brain/awh088 10.1016/j.parkreldis.2010.10.003 10.1111/1469-8986.3720127 10.1007/s00330-013-2775-4 10.1002/mds.22799 10.1002/mds.26312 10.1159/000345537 10.1016/j.expneurol.2012.01.024 10.1016/j.parkreldis.2014.03.016 10.1002/ana.10483 10.1002/mds.26191 10.1007/BF02252920 10.1016/j.neulet.2013.02.024 10.1002/mds.25286 10.1002/mds.20371 10.1016/j.clineuro.2004.12.005 10.1097/WAD.0b013e3181611011 10.1007/s00415-014-7591-5 10.1097/WNP.0b013e31818f50de 10.1016/j.jns.2011.05.034 10.3389/fneur.2013.00037 10.1001/archneur.59.9.1415 10.1212/01.WNL.0000153070.82309.D4 10.3389/fnagi.2014.00053 10.1136/jnnp-2013-305805 10.1177/089198879300600301 10.1111/j.1460-9568.2009.06892.x 10.1007/BF02259661 10.1016/j.jns.2014.05.052 10.1097/FPC.0b013e32835693f7 10.1016/j.parkreldis.2014.10.014 10.1016/S0022-510X(99)00127-6 10.1111/j.1600-0404.2007.00887.x 10.1001/archneurol.2012.1654 10.3389/fnsys.2014.00045 10.1016/j.neulet.2010.05.041 10.1136/jnnp.55.10.960 10.1093/brain/awu159 10.1002/acn3.129 10.1136/jnnp-2013-305062 10.1016/j.parkreldis.2015.04.027 10.3233/JPD-140480 10.3233/JAD-2011-110587 10.1001/archneurol.2011.725 10.1016/j.bbi.2013.07.007 10.1212/WNL.0000000000001020 10.1212/WNL.0b013e3181c7da8e 10.1111/j.1468-1331.2007.01977.x 10.1016/j.jns.2006.05.033 10.1177/089198879100400404 10.1002/mds.23287 10.1038/npp.2012.255 10.1159/000334765 10.1002/mds.26071 10.1177/1533317512470207 10.1002/mds.22158 10.1212/WNL.0000000000000483 10.1002/hbm.22499 10.1002/mds.20481 10.1002/hbm.21245 10.1002/hbm.22101 10.1016/j.parkreldis.2014.02.023 10.1111/j.1468-1331.2009.02706.x 10.1002/mds.22594 10.1007/s00702-008-0132-6 10.1136/jnnp.2006.093849 10.1002/mds.22357 10.1093/brain/awr031 10.1093/brain/awt337 10.1016/j.neulet.2006.07.037 10.1016/j.neulet.2009.10.062 10.1016/j.parkreldis.2006.04.008 10.1002/mds.22899 10.1001/archneur.61.6.865 10.3109/07853890.2013.849003 10.1002/mds.20118 10.1002/mds.23477 10.1093/brain/awf134 10.1016/j.parkreldis.2010.08.021 10.1002/mds.23319 10.1016/j.parkreldis.2015.06.013 10.1002/mds.25048 10.1001/archneur.62.8.1265 10.1001/archneur.60.3.387 10.3389/fnins.2014.00207 10.1016/j.neurobiolaging.2015.01.002 10.1016/j.parkreldis.2012.11.012 10.1159/000315036 10.1002/mds.24893 10.1212/WNL.0b013e318224af8d 10.1016/j.jns.2006.05.032 10.1002/mds.24946 10.1007/s00401-015-1392-5 10.1016/j.archger.2013.04.015 10.1016/j.jocn.2015.02.013 10.1016/j.neulet.2010.10.015 10.1002/ajmg.b.30611 10.1093/brain/123.2.340 10.1001/archneur.64.2.261 10.1002/mds.25982 10.1016/S1474-4422(12)70138-2 10.1111/ane.12365 10.14802/jmd.11014 10.1212/WNL.54.6.1272 10.1016/0013-4694(91)90134-P 10.1371/journal.pone.0064222 10.1007/s00702-011-0716-4 10.1212/WNL.0b013e3181a2e8d0 10.1371/journal.pone.0048783 10.1002/mds.20974 10.1002/hbm.20033 10.1002/mds.24045 10.1212/01.wnl.0000191154.78131.f6 10.1002/mds.22858 10.1186/alzrt255 10.1111/j.1600-0404.2005.00535.x 10.1002/mds.22522 10.1159/000371510 10.3233/JAD-132684 10.1212/WNL.0b013e31829e6f94 10.1001/jamaneurol.2015.1449 10.1371/journal.pone.0054980 10.1002/ana.22271 10.1002/mds.25040 10.1136/jnnp.2003.031237 10.1093/brain/awv211 10.1212/WNL.0b013e31829c5c86 10.1001/archgenpsychiatry.2009.106 10.1093/brain/aws318 10.1016/j.nbd.2008.12.008 10.3233/JPD-140398 10.1111/j.1600-0404.1988.tb03609.x 10.1111/ene.12785 10.1002/mds.22444 10.1002/hbm.22822 10.1136/jnnp.2007.127878 10.1159/000153432 10.1016/j.jns.2014.09.049 10.1016/j.clinph.2006.06.720 10.1007/BF02260965 10.1002/hbm.22256 10.1212/WNL.0b013e3181d55f61 10.1523/JNEUROSCI.23-15-06351.2003 10.1159/000084551 10.1016/j.parkreldis.2014.02.001 10.1002/mds.25633 10.1016/j.neurobiolaging.2014.12.006 10.1093/brain/awm322 10.1002/ana.410370215 10.1007/s00415-014-7560-z 10.1212/WNL.0b013e3181f39a78 10.1016/S0033-3182(10)70739-8 10.1016/j.ajpath.2013.12.007 10.1111/j.1468-1331.2010.02980.x 10.1159/000094871 10.1002/ana.21192 10.1159/000370110 10.1371/journal.pone.0053250 10.1371/journal.pone.0048042 10.1136/jnnp.74.4.419 10.1007/BF00169811 10.1177/0891988709332945 10.1016/j.pscychresns.2012.06.001 10.1007/s100720170039 10.1097/WNP.0b013e3181dd4fdb 10.1016/j.clinph.2013.05.001 10.1212/01.wnl.0000304050.05332.9c 10.1016/j.neuroimage.2004.01.030 10.1016/j.parkreldis.2007.11.001 10.1016/S0021-9150(99)00257-9 10.1002/mds.25104 10.1016/S1353-8020(99)00009-7 10.4161/19420889.2014.993266 10.1177/0284185113476029 10.1002/mds.23823 10.1016/j.parkreldis.2014.07.008 10.1093/brain/awp245 10.3233/JAD-2010-1289 10.1001/jamaneurol.2014.1455 10.1159/000017212 10.1001/archneurol.2011.17 10.1159/000213538 10.1007/s00259-012-2198-5 10.1016/j.parkreldis.2014.12.027 10.1002/ana.24323 10.1002/mds.20700 10.1097/WAD.0b013e31819c5ef4 10.1001/jamaneurol.2013.2110 10.1016/j.parkreldis.2008.05.002 10.1002/mds.25282 10.1097/01.WNF.0000236763.16032.60 10.1002/mds.24938 10.1016/j.parkreldis.2007.01.003 10.1016/j.parkreldis.2006.10.005 10.1016/j.jns.2011.07.047 10.1002/mds.21956 10.1002/mds.25541 10.1136/jnnp-2013-305277 10.1016/S0304-3940(01)02124-3 10.1212/WNL.0b013e3182929f62 10.1186/1471-2377-14-113 10.1007/s00415-005-0971-0 10.1002/hbm.22302 10.1016/j.parkreldis.2013.11.008 10.1111/ane.12259 10.1002/mds.870090115 10.1002/ana.23659 10.1002/mds.25857 10.1016/j.neurobiolaging.2013.06.025 10.1212/WNL.0b013e318253d54b 10.1007/s00401-010-0744-4 10.1097/01.mnm.0000243370.18883.62 10.1002/mds.22682 10.3233/JPD-120151 10.1016/j.parkreldis.2006.12.012 10.1016/j.neurobiolaging.2014.07.043 10.1002/mds.20663 10.1002/mds.22381 10.1111/j.1600-0404.2007.00838.x 10.1038/jcbfm.2012.60 10.1002/mds.25360 10.1093/brain/awp263 10.1007/s00234-004-1257-4 10.1016/j.ejrad.2015.04.014 10.1007/s00259-005-1830-z 10.1016/j.biopsych.2008.02.016 10.1093/brain/awu201 10.1016/j.neuroimage.2006.09.003 10.1016/j.neurobiolaging.2010.11.015 10.1111/ene.12137 10.1016/j.neuropsychologia.2004.08.010 10.1136/jnnp.2009.199950 10.1007/s00415-009-0119-8 10.1016/0022-510X(94)90342-5 10.3233/JPD-130206 10.1093/brain/awm313 10.1212/WNL.0b013e31827b1a07 10.1007/s00429-014-0785-x 10.1002/mds.23393 10.1371/journal.pone.0110547 10.1212/WNL.0b013e3182315259 10.1212/01.WNL.0000158422.41380.82 10.1007/s00415-008-0885-8 10.1007/s00259-009-1168-z 10.1016/j.parkreldis.2008.03.005 10.1212/WNL.0b013e3182698d4a 10.1159/000345987 10.1159/000357128 10.1002/mds.26051 10.1016/j.neulet.2003.09.076 |
| ContentType | Journal Article |
| Copyright | 2016 International Parkinson and Movement Disorder Society 2016 International Parkinson and Movement Disorder Society. |
| Copyright_xml | – notice: 2016 International Parkinson and Movement Disorder Society – notice: 2016 International Parkinson and Movement Disorder Society. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 8FD FR3 K9. NAPCQ P64 RC3 7X8 |
| DOI | 10.1002/mds.26662 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Genetics Abstracts Technology Research Database ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE Nursing & Allied Health Premium Neurosciences Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1531-8257 |
| EndPage | 881 |
| ExternalDocumentID | 4073489901 27193487 10_1002_mds_26662 MDS26662 ark_67375_WNG_XCPL4PS5_P |
| Genre | reviewArticle Journal Article Review |
| GrantInformation_xml | – fundername: Government of the Basque Country funderid: 2011111074; SAIO12‐PE12BN012; CIBERNED – fundername: Institute of Health Carlos III (ISCIII) funderid: PI08/1539; PI14/00763 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XV2 ZGI ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM YCJ 7TK 8FD FR3 K9. NAPCQ P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c5252-3995e7f80d099e92f9706abcd3b0d703b83ed56bc287f0dcd7c29163492c07843 |
| IEDL.DBID | DR2 |
| ISSN | 0885-3185 1531-8257 |
| IngestDate | Fri Jul 11 01:48:02 EDT 2025 Thu Jul 10 22:39:12 EDT 2025 Mon Sep 08 08:32:36 EDT 2025 Thu Apr 03 07:04:04 EDT 2025 Thu Apr 24 22:58:21 EDT 2025 Tue Jul 01 01:44:20 EDT 2025 Sun Sep 21 06:21:26 EDT 2025 Sun Sep 21 06:17:15 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | dementia mild cognitive impairment Parkinson's disease biomarkers |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016 International Parkinson and Movement Disorder Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5252-3995e7f80d099e92f9706abcd3b0d703b83ed56bc287f0dcd7c29163492c07843 |
| Notes | Institute of Health Carlos III (ISCIII) - No. PI08/1539; No. PI14/00763 ark:/67375/WNG-XCPL4PS5-P ArticleID:MDS26662 istex:FF46FDF0EB0F28DFA786B583428BC04A725336C9 Government of the Basque Country - No. 2011111074; No. SAIO12-PE12BN012; No. CIBERNED Nothing to report. Relevant conflicts of interests/financial disclosures Funding agencies Institute of Health Carlos III (ISCIII), grants PI08/1539 and PI14/00763; Government of the Basque Country, grants 2011111074 and SAIO12‐PE12BN012; and CIBERNED. M.D.‐A. is funded by a Basque Country Ph.D. studentship and a Jesús de Gangoiti Barrera Foundation grant. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://hdl.handle.net/10810/22968 |
| PMID | 27193487 |
| PQID | 1792699617 |
| PQPubID | 1016421 |
| PageCount | 21 |
| ParticipantIDs | proquest_miscellaneous_1808713487 proquest_miscellaneous_1793569104 proquest_journals_1792699617 pubmed_primary_27193487 crossref_citationtrail_10_1002_mds_26662 crossref_primary_10_1002_mds_26662 wiley_primary_10_1002_mds_26662_MDS26662 istex_primary_ark_67375_WNG_XCPL4PS5_P |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2016 |
| PublicationDateYYYYMMDD | 2016-06-01 |
| PublicationDate_xml | – month: 06 year: 2016 text: June 2016 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Movement disorders |
| PublicationTitleAlternate | Mov Disord |
| PublicationYear | 2016 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Compta Y, Ibarretxe-Bilbao N, Pereira JB, et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18(8):941-947. Nagano-Saito A, Habak C, Mejia-Constain B, et al. Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiol Aging 2014;35(1):223-231. Noh SW, Han YH, Mun CW, et al. Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive impairment. J Neurol Sci 2014;347(1-2):210-213. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54(6):1272-1276. Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 2010;32(7):775-779. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21(9):1343-1349. Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord 2014;20(5):503-507. Gonzalez-Aramburu I, Sanchez-Juan P, Sierra M, et al. Serum uric acid and risk of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20(6):637-639. Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006;21(1):45-49. Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009;256(3):493-498. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009;24(3):392-400. Garcia-Garcia D, Clavero P, Gasca Salas C, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging 2012;39(11):1767-1777. Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010;64(2):65-73. Melzer TR, Watts R, MacAskill MR, et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology 2013;80(20):1841-1849. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008;23(7):998-1005. Campbell MC, Markham J, Flores H, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013;81(6):520-527. Matsui H, Nishinaka K, Oda M, et al. Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. Parkinsonism Relat Disord 2007;13(3):174-181. Kamagata K, Motoi Y, Tomiyama H, et al. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur Radiol 2013;23(7):1946-1955. Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19(8):885-891. Chen KJ, Lin RT, Liu CK, Tai CT, Lai CL. Relationship between event-related potentials and frontal-subcortical dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2006;12(7):453-458. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75(10):1467-1469. Lee JE, Park B, Song SK, Sohn YH, Park HJ, Lee PH. A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov Disord 2010;25(1):28-34. Duncan GW, Firbank MJ, Yarnall AJ, et al. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease? Mov Disord 2016;31(1):103-110. Lehnert S, Jesse S, Rist W, et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012;234(2):499-505. Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 2012;263(1):226-234. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62(2):145-153. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73(4):273-278. Weintraub D, Doshi J, Koka D, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011;68(12):1562-1568. Maetzler W, Tian Y, Baur SM, et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 2012;7(10):e48042. Amboni M, Tessitore A, Esposito F, et al. Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. J Neurol 2015;262(2):425-434. Menza M, Dobkin RD, Marin H, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010;51(6):474-479. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26(10):1814-1824. Jansen Steur E, Vermes I, de Vos RA. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. Lancet 1998;351(9109):1105-1106. Jellinger K. Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012;119(3):381-382. Connolly J, Siderowf A, Clark CM, Mu D, Pratico D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn Behav Neurol 2008;21(2):83-86. Nombela C, Rowe JB, Winder-Rhodes SE, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014;137(Pt 10):2743-2758. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64(8):1404-1410. Oikawa H, Sasaki M, Ehara S, Abe T. Substantia innominata: MR findings in Parkinson's disease. Neuroradiology 2004;46(10):817-821. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61(6):865-868. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55(2):174-179. Pellecchia MT, Picillo M, Santangelo G, et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. Acta Neurol Scand 2015;131(5):275-281. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136(Pt 2):392-399. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008;22(1):54-60. Kandiah N, Zainal NH, Narasimhalu K, et al. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20(11):1203-1208. Bruck A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001;311(2):81-84. Aotsuka A, Weate SJ, Drake ME Jr, Paulson GW. Event-related potentials in Parkinson's disease. Electromyogr Clin Neurophysiol 1996;36(4):215-220. Gasca-Salas C, Estanga A, Clavero P, et al. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's Disease. J Parkinsons Dis 2014;4(4):677-686. Pellecchia MT, Santangelo G, Picillo M, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol 2013;260(2):438-444. Biundo R, Calabrese M, Weis L, et al. Anatomical correlates of cognitive functions in early Parkinson's disease patients. PLoS ONE 2013;8(5):e64222. Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol 2015;262(2):294-306. Caviness JN, Hentz JG, Belden CM, et al. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. J Parkinsons Dis 2015;5(1):117-124. Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012;11(8):679-687. Wallin A, Ekberg S, Lind K, Milos V, Granerus AK, Granerus G. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease-a rCBF scintigraphy study. Acta Neurol Scand 2007;116(6):347-354. Morita A, Kamei S, Mizutani T. Relationship between slowing of the EEG and cognitive impairment in Parkinson disease. J Clin Neur 2015; 262 2004; 22 1995; 37 2008; 39 2005; 62 2016; 31 2005; 64 1988; 78 2013; 70 2005; 65 2013; 124 2012; 18 1992; 55 2012; 11 2012; 10 2011; 487 2013; 54 2015; 138 2013; 57 2000; 11 2015; 131 2013; 52 2008; 25 2008; 26 2008; 23 2008; 21 2008; 22 2012; 27 2012; 22 2009; 66 2013; 84 2002; 79 2004; 46 2012; 39 2015; 129 2011; 4 2001; 22 2012; 34 2012; 33 2006; 117 2011; 134 2012; 32 2007; 13 2007; 14 2006; 113 2004; 55 2009; 73 2009; 72 2013; 80 2013; 213 2013; 81 2008; 255 2008; 131 2002; 59 2004; 61 2013; 28 2013; 27 1991; 54 2013; 23 2006; 253 2008; 79 1996; 36 2008; 70 2007; 34 2011; 310 2013; 19 2014; 1 2004; 75 2010; 64 2014; 4 1991; 45 2008; 64 2006; 248 2014; 9 2014; 8 2014; 7 2014; 6 2010; 74 2007; 27 1991; 4 2010; 75 2015; 5 2015; 93 2006; 12 2013; 45 2013; 541 2008; 448 2010; 120 1999; 147 2010; 81 2014; 85 2015; 9 2014; 83 2015; 7 2014; 82 2003; 74 1994; 121 2007; 116 2013; 38 2013; 33 2013; 35 2013; 34 1996; 40 2014; 184 2014 2003; 60 1996; 46 2014; 71 2013; 3 2010; 16 2013; 4 2010; 19 2010; 468 2015; 72 2010; 17 2015; 77 1993; 20 2011; 52 2014; 29 1999; 166 2013; 8 2014; 130 2007; 78 2003; 53 2014; 137 2014; 21 2009; 116 2014; 20 2010; 22 2010; 27 2010; 25 1993; 39 2006; 21 2010; 479 2015; 84 2006; 22 2006; 27 2005; 107 2014; 14 2006; 29 2011; 68 2007; 62 2011; 69 2000; 123 2007; 64 2009; 16 2009; 15 1995; 9 2010; 32 1991; 79 2011; 77 2014; 2014 2014; 42 1990; 2 2001; 311 2005; 19 2012; 234 2002; 125 2014; 37 2014; 35 2012; 119 2010; 51 2003; 23 2015; 36 2004; 127 2015; 39 2015; 30 2015; 220 2005; 20 1992; 13 2003; 18 2008; 147 2011; 17 1998; 351 1993; 6 2012; 72 2006; 406 2007; 414 2000; 54 2005; 32 2011; 26 2012; 69 2014; 561 2011; 28 2011; 27 2009; 23 2012; 83 2009; 22 2009; 24 2012; 263 2009; 132 2008; 14 2009; 256 2005; 43 2012; 79 2013; 260 2012; 78 1999; 5 2005; 44 2009; 34 1994; 9 2004; 354 2014; 347 2009; 36 2009; 30 2004; 19 2000; 37 2015; 22 2015; 21 2013; 136 2012; 7 1994; 5 2014; 343 1994; 7 2005; 58 e_1_2_13_120_1 e_1_2_13_143_1 e_1_2_13_166_1 e_1_2_13_189_1 Bernhardi R (e_1_2_13_77_1) 2015; 7 e_1_2_13_20_1 e_1_2_13_66_1 e_1_2_13_181_1 e_1_2_13_226_1 e_1_2_13_249_1 e_1_2_13_8_1 e_1_2_13_81_1 e_1_2_13_252_1 e_1_2_13_275_1 e_1_2_13_298_1 e_1_2_13_92_1 e_1_2_13_117_1 e_1_2_13_214_1 e_1_2_13_290_1 e_1_2_13_17_1 e_1_2_13_154_1 e_1_2_13_131_1 e_1_2_13_32_1 e_1_2_13_78_1 e_1_2_13_177_1 e_1_2_13_215_1 e_1_2_13_192_1 e_1_2_13_238_1 Hanafusa H (e_1_2_13_287_1) 1991; 45 e_1_2_13_70_1 e_1_2_13_241_1 e_1_2_13_264_1 e_1_2_13_203_1 e_1_2_13_105_1 e_1_2_13_88_1 e_1_2_13_128_1 e_1_2_13_29_1 e_1_2_13_165_1 e_1_2_13_142_1 e_1_2_13_21_1 e_1_2_13_44_1 e_1_2_13_67_1 e_1_2_13_104_1 e_1_2_13_188_1 e_1_2_13_9_1 e_1_2_13_248_1 e_1_2_13_82_1 Kramberger MG (e_1_2_13_268_1) 2010; 22 e_1_2_13_180_1 e_1_2_13_251_1 e_1_2_13_297_1 e_1_2_13_91_1 e_1_2_13_274_1 e_1_2_13_236_1 e_1_2_13_116_1 e_1_2_13_213_1 e_1_2_13_99_1 e_1_2_13_139_1 e_1_2_13_18_1 e_1_2_13_130_1 e_1_2_13_153_1 e_1_2_13_79_1 e_1_2_13_10_1 e_1_2_13_56_1 e_1_2_13_115_1 e_1_2_13_176_1 e_1_2_13_199_1 e_1_2_13_33_1 e_1_2_13_237_1 e_1_2_13_71_1 Gasca‐Salas C (e_1_2_13_6_1) 2014; 4 e_1_2_13_191_1 e_1_2_13_240_1 e_1_2_13_263_1 e_1_2_13_286_1 e_1_2_13_225_1 e_1_2_13_202_1 e_1_2_13_127_1 e_1_2_13_122_1 e_1_2_13_68_1 e_1_2_13_45_1 e_1_2_13_145_1 e_1_2_13_168_1 e_1_2_13_205_1 e_1_2_13_22_1 e_1_2_13_83_1 e_1_2_13_183_1 e_1_2_13_228_1 e_1_2_13_160_1 Maetzler W (e_1_2_13_42_1) 2011; 27 e_1_2_13_90_1 e_1_2_13_231_1 e_1_2_13_254_1 e_1_2_13_277_1 e_1_2_13_98_1 e_1_2_13_119_1 e_1_2_13_19_1 e_1_2_13_292_1 e_1_2_13_133_1 e_1_2_13_179_1 e_1_2_13_57_1 e_1_2_13_110_1 e_1_2_13_217_1 e_1_2_13_11_1 e_1_2_13_34_1 e_1_2_13_156_1 Peterson AL (e_1_2_13_55_1) 2013; 3 e_1_2_13_171_1 e_1_2_13_72_1 e_1_2_13_194_1 Rocha NP (e_1_2_13_63_1) 2014; 2014 Neufeld MY (e_1_2_13_270_1) 1994; 5 e_1_2_13_220_1 e_1_2_13_243_1 e_1_2_13_266_1 e_1_2_13_289_1 Williams‐Gray CH (e_1_2_13_112_1) 2007; 27 e_1_2_13_107_1 e_1_2_13_121_1 e_1_2_13_46_1 e_1_2_13_69_1 e_1_2_13_23_1 e_1_2_13_167_1 e_1_2_13_204_1 e_1_2_13_84_1 e_1_2_13_182_1 e_1_2_13_227_1 e_1_2_13_7_1 e_1_2_13_61_1 e_1_2_13_230_1 e_1_2_13_276_1 e_1_2_13_253_1 e_1_2_13_299_1 e_1_2_13_97_1 e_1_2_13_118_1 e_1_2_13_291_1 e_1_2_13_132_1 e_1_2_13_155_1 e_1_2_13_178_1 e_1_2_13_35_1 e_1_2_13_58_1 e_1_2_13_216_1 e_1_2_13_12_1 e_1_2_13_170_1 e_1_2_13_193_1 e_1_2_13_73_1 e_1_2_13_239_1 e_1_2_13_50_1 e_1_2_13_265_1 e_1_2_13_242_1 e_1_2_13_288_1 e_1_2_13_106_1 e_1_2_13_129_1 e_1_2_13_280_1 e_1_2_13_24_1 Maetzler W (e_1_2_13_43_1) 2010; 19 e_1_2_13_47_1 e_1_2_13_185_1 e_1_2_13_207_1 e_1_2_13_101_1 e_1_2_13_147_1 e_1_2_13_124_1 e_1_2_13_85_1 e_1_2_13_62_1 e_1_2_13_162_1 e_1_2_13_233_1 e_1_2_13_256_1 e_1_2_13_279_1 e_1_2_13_96_1 e_1_2_13_210_1 e_1_2_13_271_1 e_1_2_13_294_1 e_1_2_13_13_1 e_1_2_13_36_1 e_1_2_13_59_1 e_1_2_13_219_1 e_1_2_13_158_1 e_1_2_13_196_1 e_1_2_13_135_1 e_1_2_13_51_1 e_1_2_13_74_1 e_1_2_13_173_1 e_1_2_13_150_1 e_1_2_13_222_1 e_1_2_13_245_1 e_1_2_13_4_1 e_1_2_13_109_1 e_1_2_13_283_1 e_1_2_13_260_1 e_1_2_13_25_1 e_1_2_13_48_1 e_1_2_13_100_1 e_1_2_13_169_1 e_1_2_13_206_1 e_1_2_13_123_1 e_1_2_13_86_1 e_1_2_13_146_1 e_1_2_13_40_1 e_1_2_13_184_1 e_1_2_13_229_1 e_1_2_13_161_1 e_1_2_13_232_1 e_1_2_13_255_1 e_1_2_13_95_1 e_1_2_13_278_1 e_1_2_13_293_1 e_1_2_13_14_1 e_1_2_13_111_1 e_1_2_13_37_1 e_1_2_13_218_1 e_1_2_13_134_1 e_1_2_13_157_1 e_1_2_13_75_1 e_1_2_13_52_1 e_1_2_13_172_1 e_1_2_13_195_1 Aotsuka A (e_1_2_13_295_1) 1996; 36 e_1_2_13_221_1 e_1_2_13_5_1 e_1_2_13_244_1 e_1_2_13_267_1 e_1_2_13_108_1 e_1_2_13_282_1 e_1_2_13_49_1 e_1_2_13_141_1 e_1_2_13_164_1 e_1_2_13_209_1 e_1_2_13_26_1 e_1_2_13_126_1 e_1_2_13_87_1 e_1_2_13_187_1 Morita A (e_1_2_13_281_1) 2011; 28 e_1_2_13_64_1 e_1_2_13_103_1 e_1_2_13_41_1 e_1_2_13_273_1 e_1_2_13_296_1 e_1_2_13_94_1 e_1_2_13_235_1 e_1_2_13_258_1 e_1_2_13_138_1 e_1_2_13_212_1 e_1_2_13_250_1 e_1_2_13_15_1 e_1_2_13_38_1 e_1_2_13_152_1 e_1_2_13_137_1 e_1_2_13_175_1 e_1_2_13_53_1 e_1_2_13_76_1 e_1_2_13_114_1 e_1_2_13_198_1 e_1_2_13_259_1 e_1_2_13_30_1 e_1_2_13_190_1 e_1_2_13_262_1 e_1_2_13_285_1 e_1_2_13_224_1 e_1_2_13_247_1 e_1_2_13_2_1 e_1_2_13_201_1 e_1_2_13_149_1 e_1_2_13_27_1 e_1_2_13_163_1 e_1_2_13_208_1 e_1_2_13_102_1 e_1_2_13_125_1 e_1_2_13_148_1 e_1_2_13_186_1 e_1_2_13_65_1 e_1_2_13_80_1 e_1_2_13_140_1 Moccia M (e_1_2_13_60_1) 2014 e_1_2_13_93_1 e_1_2_13_234_1 e_1_2_13_257_1 e_1_2_13_211_1 e_1_2_13_39_1 e_1_2_13_272_1 e_1_2_13_16_1 e_1_2_13_113_1 e_1_2_13_136_1 e_1_2_13_159_1 e_1_2_13_174_1 e_1_2_13_197_1 e_1_2_13_31_1 e_1_2_13_54_1 e_1_2_13_151_1 e_1_2_13_284_1 e_1_2_13_223_1 e_1_2_13_269_1 e_1_2_13_3_1 e_1_2_13_246_1 Hwang KS (e_1_2_13_144_1) 2013; 3 e_1_2_13_89_1 e_1_2_13_200_1 e_1_2_13_28_1 e_1_2_13_261_1 |
| References_xml | – reference: Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75(10):1467-1469. – reference: Caviness JN, Hentz JG, Evidente VG, et al. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord 2007;13(6):348-354. – reference: Lehnert S, Jesse S, Rist W, et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012;234(2):499-505. – reference: Danti S, Toschi N, Diciotti S, et al. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality. Eur J Neurol 2015;22(12):1564-1572. – reference: Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014;184(4):966-975. – reference: Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64(2):224-229. – reference: Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84(11):1258-1264. – reference: Rektorova I, Krajcovicova L, Marecek R, Novakova M, Mikl M. Default mode network connectivity patterns associated with visual processing at different stages of Parkinson's disease. J Alzheimers Dis 2014;42(suppl 3):S217-S228. – reference: Shoji Y, Nishio Y, Baba T, et al. Neural substrates of cognitive subtypes in Parkinson's disease: a 3-year longitudinal study. PLoS ONE 2014;9(10):e110547. – reference: Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70(16 Pt 2):1470-1477. – reference: Derejko M, Slawek J, Wieczorek D, Brockhuis B, Dubaniewicz M, Lass P. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl Med Commun 2006;27(12):945-951. – reference: Petrou M, Bohnen NI, Muller ML, Koeppe RA, Albin RL, Frey KA. Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012;79(11):1161-1167. – reference: Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73(4):273-278. – reference: Compta Y, Ibarretxe-Bilbao N, Pereira JB, et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18(8):941-947. – reference: Pellecchia MT, Santangelo G, Picillo M, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol 2013;260(2):438-444. – reference: Schlede N, Zimmermann R, Ehrensperger MM, et al. Clinical EEG in cognitively impaired patients with Parkinson's Disease. J Neurol Sci 2011;310(1-2):75-78. – reference: Camicioli R, Gee M, Bouchard TP, et al. Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism Relat Disord 2009;15(3):187-195. – reference: Theilmann RJ, Reed JD, Song DD, et al. White-matter changes correlate with cognitive functioning in Parkinson's disease. Front Neurol 2013;4:37. – reference: Choi SH, Jung TM, Lee JE, Lee SK, Sohn YH, Lee PH. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging 2012;33(7):1265-1272. – reference: Caviness JN, Hentz JG, Belden CM, et al. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. J Parkinsons Dis 2015;5(1):117-124. – reference: Liu RS, Lin KN, Wang SJ, et al. Cognition and 99Tcm-HMPAO SPECT in Parkinson's disease. Nucl Med Commun 1992;13(10):744-748. – reference: Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75(12):1055-1061. – reference: Zheng Z, Shemmassian S, Wijekoon C, Kim W, Bookheimer SY, Pouratian N. DTI correlates of distinct cognitive impairments in Parkinson's disease. Hum Brain Mapp 2014;35(4):1325-1333. – reference: Baggio HC, Sala-Llonch R, Segura B, et al. Functional brain networks and cognitive deficits in Parkinson's disease. Hum Brain Mapp 2014;35(9):4620-4634. – reference: Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9(1):92-97. – reference: Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136(Pt 2):392-399. – reference: Shimada H, Shinotoh H, Hirano S, et al. beta-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013;28(2):169-175. – reference: Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25(15):2516-2523. – reference: Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. Mov Disord 2008;23(11):1580-1587. – reference: Jellinger K. Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012;119(3):381-382. – reference: Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology 1996;46(3):678-681. – reference: Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005;32(10):1176-1185. – reference: Melzer TR, Watts R, MacAskill MR, et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology 2013;80(20):1841-1849. – reference: Lorenz R, Samnick S, Dillmann U, et al. Nicotinic alpha4beta2 acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurol Scand 2014;130(3):164-171. – reference: Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134(Pt 5):1493-1505. – reference: Williams-Gray CH, Hampshire A, Barker RA, Owen AM. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain 2008;131(Pt 2):397-408. – reference: Jesse S, Lehnert S, Jahn O, et al. Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS ONE 2012;7(11):e48783. – reference: Kenny ER, Burton EJ, O'Brien JT. A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008;26(3):218-225. – reference: Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011;69(4):655-663. – reference: Zarei M, Ibarretxe-Bilbao N, Compta Y, et al. Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84(8):875-881. – reference: Celebi O, Temucin CM, Elibol B, Saka E. Short latency afferent inhibition in Parkinson's disease patients with dementia. Mov Disord 2012;27(8):1052-1055. – reference: Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007;78(3):254-259. – reference: Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26(10):1814-1824. – reference: Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 2008;14(7):576-578. – reference: Guerini FR, Beghi E, Riboldazzi G, et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol 2009;16(11):1240-1245. – reference: Petrou M, Dwamena BA, Foerster BR, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 2015;30(7):928-935. – reference: Mito Y, Yoshida K, Yabe I, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005;107(5):396-403. – reference: Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 2010;32(7):775-779. – reference: Lebedev AV, Westman E, Simmons A, et al. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Front Syst Neurosci 2014;8:45. – reference: Connolly J, Siderowf A, Clark CM, Mu D, Pratico D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn Behav Neurol 2008;21(2):83-86. – reference: Beavan MS, Schapira AH. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 2013;45(8):511-521. – reference: Seto-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord 2012;27(3):393-399. – reference: Matsui H, Nishinaka K, Oda M, Kubori T, Udaka F. Auditory event-related potentials in Parkinson's disease: prominent correlation with attention. Parkinsonism Relat Disord 2007;13(7):394-398. – reference: Morita A, Kamei S, Mizutani T. Relationship between slowing of the EEG and cognitive impairment in Parkinson disease. J Clin Neurophysiol 2011;28(4):384-387. – reference: De Marco EV, Tarantino P, Rocca FE, et al. Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2008;147(3):403-407. – reference: Segura B, Baggio HC, Marti MJ, et al. Cortical thinning associated with mild cognitive impairment in Parkinson's disease. Mov Disord 2014;29(12):1495-1503. – reference: Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65(11):1716-1722. – reference: Aotsuka A, Weate SJ, Drake ME Jr, Paulson GW. Event-related potentials in Parkinson's disease. Electromyogr Clin Neurophysiol 1996;36(4):215-220. – reference: Hwang KS, Beyer MK, Green AE, et al. Mapping cortical atrophy in Parkinson's disease patients with dementia. J Parkinsons Dis 2013;3(1):69-76. – reference: Bruck A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001;311(2):81-84. – reference: Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012;27(8):965-973. – reference: Parnetti L, Farotti L, Eusebi P, et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front Aging Neurosci 2014;6:53. – reference: Wang SJ, Liu RS, Liu HC, et al. Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization. Eur J Nucl Med 1993;20(4):339-344. – reference: Huang C, Ravdin LD, Nirenberg MJ, et al. Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord 2013;35(3-4):183-196. – reference: Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25(15):2682-2685. – reference: Bialecka M, Kurzawski M, Roszmann A, et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci Lett 2014;561:86-90. – reference: Kramberger MG, Stukovnik V, Cus A, et al. Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment. Psychiatr Danub 2010;22(3):446-449. – reference: Bousleiman H, Zimmermann R, Ahmed S, et al. Power spectra for screening parkinsonian patients for mild cognitive impairment. Ann Clin Transl Neurol 2014;1(11):884-890. – reference: Matsui H, Nishinaka K, Oda M, Niikawa H, Kubori T, Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007;116(3):177-181. – reference: Picton TW, Bentin S, Berg P, et al. Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria. Psychophysiology 2000;37(2):127-152. – reference: Pereira JB, Svenningsson P, Weintraub D, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 2014;82(22):2017-2025. – reference: Neufeld MY, Blumen S, Aitkin I, Parmet Y, Korczyn AD. EEG frequency analysis in demented and nondemented parkinsonian patients. Dementia 1994;5(1):23-28. – reference: Nishio Y, Hirayama K, Takeda A, et al. Corticolimbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol 2010;17(8):1090-1097. – reference: Song IU, Kim YD, Cho HJ, Chung SW. Is neuroinflammation involved in the development of dementia in patients with Parkinson's disease? Intern Med 2013;52(16):1787-1792. – reference: Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17(1):61-64. – reference: Camicioli RM, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord 2009;24(2):176-182. – reference: Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60(3):387-392. – reference: Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord 2014;20(5):503-507. – reference: Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010;16(10):666-670. – reference: Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120(6):827-828. – reference: Chen KJ, Lin RT, Liu CK, Tai CT, Lai CL. Relationship between event-related potentials and frontal-subcortical dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2006;12(7):453-458. – reference: Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol Scand 2006;113(1):14-17. – reference: Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74(11):885-892. – reference: Soikkeli R, Partanen J, Soininen H, Paakkonen A, Riekkinen P Sr. Slowing of EEG in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1991;79(3):159-165. – reference: Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord 2013;19(3):329-334. – reference: O'Mahony D, Rowan M, Feely J, O'Neill D, Walsh JB, Coakley D. Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison. Gerontology 1993;39(4):228-240. – reference: Nagano-Saito A, Habak C, Mejia-Constain B, et al. Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiol Aging 2014;35(1):223-231. – reference: Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 2014;6(3):25. – reference: Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013;81(4):346-352. – reference: Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69(11):1445-1452. – reference: Pappata S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77(14):1357-1362. – reference: Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006;21(1):45-49. – reference: Scalzo P, Kummer A, Cardoso F, Teixeira AL. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010;468(1):56-58. – reference: Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci Lett 2007;414(2):141-144. – reference: Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19(8):717-724. – reference: Kuiper MA, Mulder C, van Kamp GJ, Scheltens P, Wolters EC. Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J Neural Transm Park Dis Dement Sect 1994;7(2):109-114. – reference: Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry 2003;74(4):419-422. – reference: Toda K, Tachibana H, Sugita M, Konishi K. P300 and reaction time in Parkinson's disease. J Geriatr Psychiatry Neurol 1993;6(3):131-136. – reference: Brockmann K, Srulijes K, Pflederer S, et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015;30(3):407-411. – reference: Deng B, Zhang Y, Wang L, et al. Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson's disease. Am J Alzheimers Dis Other Demen 2013;28(2):154-164. – reference: Nagano-Saito A, Kato T, Arahata Y, et al. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 2004;22(2):553-561. – reference: Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013;70(5):580-586. – reference: Lee SH, Kim SS, Tae WS, Lee SY, Lee KU, Jhoo J. Brain volumetry in Parkinson's disease with and without dementia: where are the differences? Acta Radiol 2013;54(5):581-586. – reference: Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58(5):773-776. – reference: Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014;29(5):634-650. – reference: Christopher L, Duff-Canning S, Koshimori Y, et al. Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Ann Neurol 2015;77(2):269-280. – reference: Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol 2015;129(4):527-540. – reference: Borroni B, Premi E, Formenti A, et al. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. Parkinsonism Relat Disord 2015;21(9):1049-1055. – reference: Mak E, Zhou J, Tan LC, Au WL, Sitoh YY, Kandiah N. Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. J Neurol Neurosurg Psychiatry 2014;85(5):576-580. – reference: Wennström M, Surova Y, Hall S, et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013;8(1):e53250. – reference: Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010;64(2):65-73. – reference: Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54(6):1272-1276. – reference: Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55(2):174-179. – reference: Kandiah N, Zainal NH, Narasimhalu K, et al. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20(11):1203-1208. – reference: Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol 2009;22(3):166-170. – reference: Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83(2):188-194. – reference: Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S26-S36; discussion S36-28. – reference: Gonzalez-Aramburu I, Sanchez-Juan P, Sierra M, et al. Serum uric acid and risk of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014;20(6):637-639. – reference: Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010;25(6):687-695. – reference: Menza M, Dobkin RD, Marin H, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010;51(6):474-479. – reference: Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003;18(7):784-790. – reference: Chen B, Fan GG, Liu H, Wang S. Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status. Eur J Radiol 2015;84(7):1318-1324. – reference: Paschali A, Messinis L, Lyros E, et al. Neuropsychological functions and rCBF SPECT in Parkinson's disease patients considered candidates for deep brain stimulation. Eur J Nucl Med Mol Imaging 2009;36(11):1851-1858. – reference: Jansen Steur E, Vermes I, de Vos RA. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. Lancet 1998;351(9109):1105-1106. – reference: Compta Y, Ezquerra M, Munoz E, et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta-amyloid in Parkinson disease. Neurosci Lett 2011;487(2):169-173. – reference: Moccia M, Picillo M, Erro R, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? Parkinsonism Relat Disord 2014;20(7):772-775. – reference: Gasca-Salas C, Estanga A, Clavero P, et al. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's Disease. J Parkinsons Dis 2014;4(4):677-686. – reference: Liu C, Cholerton B, Shi M, et al. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2015;21(3):271-276. – reference: Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008;22(1):54-60. – reference: Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349-356. – reference: Beyer MK, Alves G, Hwang KS, et al. Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson's disease. Mov Disord 2013;28(3):302-310. – reference: Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov Disord 2005;20(8):989-994. – reference: Garcia-Diaz AI, Segura B, Baggio HC, et al. Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease. Parkinsonism Relat Disord 2014;20(12):1405-1410. – reference: Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72(17):1487-1494. – reference: Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72(4):587-598. – reference: Matsui H, Udaka F, Miyoshi T, et al. N-isopropyl-p- 123I iodoamphetamine single photon emission computed tomography study of Parkinson's disease with dementia. Intern Med 2005;44(10):1046-1050. – reference: Song IU, Chung YA, Chung SW, Jeong J. Early diagnosis of Alzheimer's disease and Parkinson's disease associated with dementia using cerebral perfusion SPECT. Dement Geriatr Cogn Disord 2014;37(5-6):276-285. – reference: Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008;131(Pt 3):690-705. – reference: Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2014;85(1):7-16. – reference: Mielke MM, Maetzler W, Haughey NJ, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS ONE 2013;8(9):e73094. – reference: Li Z, Zhang J, Sun H. Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment. J Clin Neurosci 2015;22(8):1268-1271. – reference: Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19(8):885-891. – reference: Morales DA, Vives-Gilabert Y, Gomez-Anson B, et al. Predicting dementia development in Parkinson's disease using Bayesian network classifiers. Psychiatry Res 2013;213(2):92-98. – reference: Song IU, Kim JS, Park IS, et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). Arch Gerontol Geriatr 2013;57(3):288-291. – reference: Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 2014;71(11):1405-1412. – reference: Nombela C, Rowe JB, Winder-Rhodes SE, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014;137(Pt 10):2743-2758. – reference: Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012;11(8):679-687. – reference: Campbell MC, Markham J, Flores H, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013;81(6):520-527. – reference: Hosokai Y, Nishio Y, Hirayama K, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009;24(6):854-862. – reference: Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22(3):236-245. – reference: Agosta F, Canu E, Stefanova E, et al. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp 2014;35(5):1921-1929. – reference: Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008;255(9):1324-1331. – reference: Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004;354(3):177-180. – reference: Bosboom JL, Stoffers D, Wolters E, Stam CJ, Berendse HW. MEG resting state functional connectivity in Parkinson's disease related dementia. J Neural Transm 2009;116(2):193-202. – reference: Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord 2012;27(6):727-734. – reference: Bokura H, Yamaguchi S, Kobayashi S. Event-related potentials for response inhibition in Parkinson's disease. Neuropsychologia 2005;43(6):967-975. – reference: Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39(3):1027-1033. – reference: Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127(Pt 4):791-800. – reference: Peterson AL, Murchison C, Zabetian C, et al. Memory, mood, and vitamin d in persons with Parkinson's disease. J Parkinsons Dis 2013;3(4):547-555. – reference: Pellecchia MT, Picillo M, Santangelo G, et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. Acta Neurol Scand 2015;131(5):275-281. – reference: Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64(10):850-855. – reference: Winder-Rhodes SE, Hampshire A, Rowe JB, et al. Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiol Aging 2015;36(3):1519-1528. – reference: Moccia M, Picillo M, Erro R, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. Eur J Neurol 2014. – reference: Ma J, Jiang Q, Xu J, et al. Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord 2015;93(5-6):251-256. – reference: Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012;27(4):512-518. – reference: van Beilen M, Leenders KL. Putamen FDOPA uptake and its relationship tot cognitive functioning in PD. J Neurol Sci 2006;248(1-2):68-71. – reference: Oikawa H, Sasaki M, Ehara S, Abe T. Substantia innominata: MR findings in Parkinson's disease. Neuroradiology 2004;46(10):817-821. – reference: Kamei S, Morita A, Serizawa K, Mizutani T, Hirayanagi K. Quantitative EEG analysis of executive dysfunction in Parkinson disease. J Clin Neurophysiol 2010;27(3):193-197. – reference: Nobili F, Campus C, Arnaldi D, et al. Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study. Mov Disord 2010;25(1):35-43. – reference: Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001;22(1):45-46. – reference: Matsui H, Nishinaka K, Oda M, et al. Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. Parkinsonism Relat Disord 2007;13(3):174-181. – reference: Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. Neurosci Lett 2008;448(1):20-23. – reference: Nishioka K, Ross OA, Ishii K, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 2009;24(12):1811-1819. – reference: Nie K, Zhang Y, Gan R, et al. Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. Neurosci Lett 2013;541:111-115. – reference: Biundo R, Calabrese M, Weis L, et al. Anatomical correlates of cognitive functions in early Parkinson's disease patients. PLoS ONE 2013;8(5):e64222. – reference: Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-844. – reference: Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009;256(3):493-498. – reference: Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009;24(3):392-400. – reference: Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132(Pt 11):2958-2969. – reference: Amboni M, Tessitore A, Esposito F, et al. Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. J Neurol 2015;262(2):425-434. – reference: Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22(3):200-208. – reference: Kamagata K, Motoi Y, Tomiyama H, et al. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur Radiol 2013;23(7):1946-1955. – reference: Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34(2):714-723. – reference: Agosta F, Canu E, Stojkovic T, et al. The topography of brain damage at different stages of Parkinson's disease. Hum Brain Mapp 2013;34(11):2798-2807. – reference: Bosboom JL, Stoffers D, Stam CJ, et al. Resting state oscillatory brain dynamics in Parkinson's disease: an MEG study. Clin Neurophysiol 2006;117(11):2521-2531. – reference: Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40(3):399-410. – reference: Lewis SJ, Shine JM, Duffy S, Halliday G, Naismith SL. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov Disord 2012;27(10):1262-1267. – reference: Hattori T, Orimo S, Aoki S, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012;33(3):727-739. – reference: Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord 2015;21(7):758-764. – reference: Siepel FJ, Bronnick KS, Booij J, et al. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. Mov Disord 2014;29(14):1802-1808. – reference: Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005;62(2):281-285. – reference: Filoteo JV, Reed JD, Litvan I, Harrington DL. Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. Mov Disord 2014;29(3):360-367. – reference: Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52(6):848-855. – reference: von Bernhardi R, Eugenin-von Bernhardi L, Eugenin J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci 2015;7:124. – reference: Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79(12):1331-1338. – reference: Garcia-Garcia D, Clavero P, Gasca Salas C, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging 2012;39(11):1767-1777. – reference: Somme JH, Gomez-Esteban JC, Molano A, Tijero B, Lezcano E, Zarranz JJ. Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1). J Neurol Sci 2011;310(1-2):86-89. – reference: Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012;32(8):1609-1617. – reference: Tanaka H, Koenig T, Pascual-Marqui RD, Hirata K, Kochi K, Lehmann D. Event-related potential and EEG measures in Parkinson's disease without and with dementia. Dement Geriatr Cogn Disord 2000;11(1):39-45. – reference: Maetzler W, Stapf AK, Schulte C, et al. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis 2011;27(1):119-126. – reference: Lucero C, Campbell MC, Flores H, Maiti B, Perlmutter JS, Foster ER. Cognitive reserve and beta-amyloid pathology in Parkinson disease. Parkinsonism Relat Disord 2015;21(8):899-904. – reference: Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009;24(10):1437-1444. – reference: Koller WC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995;37(2):242-245. – reference: Duncan GW, Firbank MJ, Yarnall AJ, et al. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease? Mov Disord 2016;31(1):103-110. – reference: Wallin A, Ekberg S, Lind K, Milos V, Granerus AK, Granerus G. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease-a rCBF scintigraphy study. Acta Neurol Scand 2007;116(6):347-354. – reference: Nobili F, Abbruzzese G, Morbelli S, et al. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009;24(3):414-421. – reference: Spampinato U, Habert MO, Mas JL, et al. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1991;54(9):787-792. – reference: Pang S, Borod JC, Hernandez A, et al. The auditory P 300 correlates with specific cognitive deficits in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1990;2(4):249-264. – reference: Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009;34(1):107-112. – reference: Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007;27(18):4832-4838. – reference: Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23(15):6351-6356. – reference: Domitrz I, Friedman A. Electroencephalography of demented and non-demented Parkinson's disease patients. Parkinsonism Relat Disord 1999;5(1-2):37-41. – reference: Hoogland J, de Bie RM, Williams-Gray CH, Muslimovic D, Schmand B, Post B. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010;25(15):2550-2554. – reference: Gonzalez-Redondo R, Garcia-Garcia D, Clavero P, et al. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain 2014;137(Pt 8):2356-2367. – reference: Koshimori Y, Segura B, Christopher L, et al. Imaging changes associated with cognitive abnormalities in Parkinson's disease. Brain Struct Funct 2015;220(4):2249-2261. – reference: Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011;26(2):289-296. – reference: Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005;64(5):861-865. – reference: Song IU, Kim YD, Cho HJ, Chung SW, Chung YA. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord 2013;27(1):51-55. – reference: Troster AI, Fields JA, Paolo AM, Koller WC. Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease. J Neurol Sci 2006;248(1-2):62-67. – reference: Angelucci F, Peppe A, Carlesimo GA, et al. A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease. Front Hum Neurosci 2015;9:130. – reference: Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21(4):456-461. – reference: Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21(9):1343-1349. – reference: Pereira JB, Aarsland D, Ginestet CE, et al. Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. Hum Brain Mapp 2015;36(8):2980-2995. – reference: Junque C, Ramirez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005;20(5):540-544. – reference: Meyer PM, Strecker K, Kendziorra K, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009;66(8):866-877. – reference: de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005;62(8):1265-1269. – reference: Ibarretxe-Bilbao N, Junque C, Tolosa E, et al. Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci 2009;30(6):1162-1171. – reference: Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006;29(6):305-311. – reference: Bialecka M, Kurzawski M, Roszmann A, et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet Genomics 2012;22(10):716-724. – reference: Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 2012;263(1):226-234. – reference: Kasama S, Tachibana H, Kawabata K, Yoshikawa H. Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three-dimensional stereotactic surface projection imaging. Dement Geriatr Cogn Disord 2005;19(5-6):266-275. – reference: Hanganu A, Bedetti C, Jubault T, et al. Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Mov Disord 2013;28(10):1360-1369. – reference: Hattori N, Yabe I, Hirata K, et al. Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT. Clin Nucl Med 2013;38(5):315-320. – reference: Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79(3):458-461. – reference: Yu SY, Zuo LJ, Wang F, et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol 2014;14(1):113. – reference: Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14(12):1357-1362. – reference: Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24(15):2203-2210. – reference: Lee JE, Park B, Song SK, Sohn YH, Park HJ, Lee PH. A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov Disord 2010;25(1):28-34. – reference: Rocha NP, Scalzo PL, Barbosa IG, et al. Cognitive status correlates with CXCL10/IP-10 levels in Parkinson's disease. Parkinsons Dis 2014;2014:903796. – reference: Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008;23(7):998-1005. – reference: Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009;23(3):295-297. – reference: Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15(2):88-93. – reference: Compta Y, Santamaria J, Ratti L, et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009;132(Pt 12):3308-3317. – reference: Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000;123(Pt 2):340-352. – reference: Kawabata K, Tachibana H, Sugita M. Cerebral blood flow and dementia in Parkinson's disease. J Geriatr Psychiatry Neurol 1991;4(4):194-203. – reference: Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78(18):1434-1440. – reference: Hanafusa H, Motomura N, Fukai M. Event-related potentials in senile dementia of Alzheimer's type, multiinfarct dementia and Parkinson's disease. Jpn J Psychiatry Neurol 1991;45(3):667-670. – reference: Weintraub D, Doshi J, Koka D, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011;68(12):1562-1568. – reference: Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80(1):85-91. – reference: Ekman U, Eriksson J, Forsgren L, et al. Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment. Front Neurosci 2014;8:207. – reference: Kim HJ, Lee JE, Shin SJ, Sohn YH, Lee PH. Analysis of the substantia innominata volume in patients with Parkinson's disease with dementia, dementia with lewy bodies, and Alzheimer's disease. J Mov Disord 2011;4(2):68-72. – reference: Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60(12):1745-1748. – reference: Norris SE, Friedrich MG, Mitchell TW, Truscott RJ, Else PL. Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. Neurobiol Aging 2015;36(4):1659-1669. – reference: Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol 2015;262(2):294-306. – reference: Summerfield C, Gomez-Anson B, Tolosa E, et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002;59(9):1415-1420. – reference: Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253(2):242-247. – reference: Serizawa K, Kamei S, Morita A, et al. Comparison of quantitative EEGs between Parkinson disease and age-adjusted normal controls. J Clin Neurophysiol 2008;25(6):361-366. – reference: Setó-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011;68(3):359-364. – reference: Ito J. Somatosensory event-related potentials (ERPs) in patients with different types of dementia. J Neurol Sci 1994;121(2):139-146. – reference: Kamagata K, Motoi Y, Abe O, et al. White matter alteration of the cingulum in Parkinson disease with and without dementia: evaluation by diffusion tensor tract-specific analysis. Am J Neuroradiol 2012;33(5):890-895. – reference: Olde Dubbelink KT, Schoonheim MM, Deijen JB, Twisk JW, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 2014;83(22):2046-2053. – reference: Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74(1):77-84. – reference: Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62(2):145-153. – reference: Jasinska-Myga B, Opala G, Goetz CG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 2007;64(2):261-265. – reference: Pagonabarraga J, Gomez-Anson B, Rotger R, et al. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease. Dement Geriatr Cogn Disord 2012;34(5-6):312-318. – reference: Noh SW, Han YH, Mun CW, et al. Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive impairment. J Neurol Sci 2014;347(1-2):210-213. – reference: Maetzler W, Tian Y, Baur SM, et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 2012;7(10):e48042. – reference: Vranová HP, Henykova E, Kaiserova M, et al. Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci 2014;343(1-2):120-124. – reference: Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiol Aging 2015;36(1):476-484. – reference: O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61(6):865-868. – reference: Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS ONE 2013;8(1):e54980. – reference: Pratico D. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999;147(1):1-10. – reference: Bodis-Wollner I, Borod JC, Cicero B, et al. Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;9(2-3):197-209. – reference: Hudson G, Stutt A, Eccles M, et al. Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease. Neurosci Lett 2010;479(2):123-125. – reference: Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013;38(6):938-949. – reference: Yarnall AJ, Rochester L, Baker MR, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease? Mov Disord 2013;28(9):1285-1288. – reference: Rektorova I, Krajcovicova L, Marecek R, Mikl M. Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia. Neurodegener Dis 2012;10(1-4):232-237. – reference: Ito K, Nagano-Saito A, Kato T, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002;125(Pt 6):1358-1365. – reference: Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov Disord 2005;20(8):999-1005. – reference: Neufeld MY, Inzelberg R, Korczyn AD. EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand 1988;78(1):1-5. – reference: Zimmermann R, Gschwandtner U, Hatz F, et al. Correlation of EEG slowing with cognitive domains in nondemented patients with Parkinson's disease. Dement Geriatr Cogn Disord 2015;39(3-4):207-214. – reference: Tokutake T, Ishikawa A, Yoshimura N, et al. Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. Parkinsonism Relat Disord 2014;20(2):262-264. – reference: Bohnen NI, Albin RL, Muller ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol 2015;72(2):194-200. – reference: Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64(8):1404-1410. – reference: Witt SN. Lipid disequilibrium in biological membranes, a possible pathway to neurodegeneration. Commun Integr Biol 2014;7(6):e993266. – reference: Christopher L, Marras C, Duff-Canning S, et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain 2014;137(Pt 2):565-575. – reference: Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33:183-189. – reference: Mak E, Su L, Williams GB, et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2015;138(Pt 10):2974-2986. – reference: Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166(2):141-151. – reference: Blazquez L, Otaegui D, Saenz A, et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci Lett 2006;406(3):235-239. – reference: Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81(10):1080-1086. – reference: Chou KL, Lenhart A, Koeppe RA, Bohnen NI. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord 2014;20(10):1076-1080. – reference: Fonseca LC, Tedrus GM, Carvas PN, Machado EC. Comparison of quantitative EEG between patients with Alzheimer's disease and those with Parkinson's disease dementia. Clin Neurophysiol 2013;124(10):1970-1974. – reference: Klassen BT, Hentz JG, Shill HA, et al. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology 2011;77(2):118-124. – reference: Maetzler W, Schmid B, Synofzik M, et al. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 2010;19(3):937-942. – reference: Backstrom DC, Eriksson Domellof M, Linder J, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson Disease. JAMA Neurol 2015;72(10):1175-1182. – reference: Pellecchia MT, Santangelo G, Picillo M, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson's disease. Eur J Neurol 2014;21(5):802-807. – reference: Sawada H, Udaka F, Kameyama M, et al. SPECT findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry 1992;55(10):960-963. – volume: 4 start-page: 677 issue: 4 year: 2014 end-page: 686 article-title: Longitudinal assessment of the pattern of cognitive decline in non‐demented patients with advanced Parkinson's Disease publication-title: J Parkinsons Dis – volume: 22 start-page: 716 issue: 10 year: 2012 end-page: 724 article-title: Association of COMT, MTHFR, and SLC19A1(RFC‐1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease publication-title: Pharmacogenet Genomics – volume: 17 start-page: 1090 issue: 8 year: 2010 end-page: 1097 article-title: Corticolimbic gray matter loss in Parkinson's disease without dementia publication-title: Eur J Neurol – volume: 54 start-page: 787 issue: 9 year: 1991 end-page: 792 article-title: (99mTc)‐HM‐PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type publication-title: J Neurol Neurosurg Psychiatry – volume: 4 start-page: 194 issue: 4 year: 1991 end-page: 203 article-title: Cerebral blood flow and dementia in Parkinson's disease publication-title: J Geriatr Psychiatry Neurol – volume: 51 start-page: 474 issue: 6 year: 2010 end-page: 479 article-title: The role of inflammatory cytokines in cognition and other non‐motor symptoms of Parkinson's disease publication-title: Psychosomatics – volume: 35 start-page: 1921 issue: 5 year: 2014 end-page: 1929 article-title: Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage publication-title: Hum Brain Mapp – volume: 29 start-page: 1495 issue: 12 year: 2014 end-page: 1503 article-title: Cortical thinning associated with mild cognitive impairment in Parkinson's disease publication-title: Mov Disord – volume: 22 start-page: 1564 issue: 12 year: 2015 end-page: 1572 article-title: Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality publication-title: Eur J Neurol – volume: 21 start-page: 1049 issue: 9 year: 2015 end-page: 1055 article-title: Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia publication-title: Parkinsonism Relat Disord – volume: 3 start-page: 69 issue: 1 year: 2013 end-page: 76 article-title: Mapping cortical atrophy in Parkinson's disease patients with dementia publication-title: J Parkinsons Dis – volume: 80 start-page: 85 issue: 1 year: 2013 end-page: 91 article-title: Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia publication-title: Neurology – volume: 7 start-page: e48042 issue: 10 year: 2012 article-title: Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia publication-title: PLoS One – volume: 354 start-page: 177 issue: 3 year: 2004 end-page: 180 article-title: Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia publication-title: Neurosci Lett – volume: 12 start-page: 453 issue: 7 year: 2006 end-page: 458 article-title: Relationship between event‐related potentials and frontal‐subcortical dysfunction in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 54 start-page: 581 issue: 5 year: 2013 end-page: 586 article-title: Brain volumetry in Parkinson's disease with and without dementia: where are the differences? publication-title: Acta Radiol – volume: 46 start-page: 678 issue: 3 year: 1996 end-page: 681 article-title: Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study publication-title: Neurology – volume: 262 start-page: 425 issue: 2 year: 2015 end-page: 434 article-title: Resting‐state functional connectivity associated with mild cognitive impairment in Parkinson's disease publication-title: J Neurol – volume: 22 start-page: 200 issue: 3 year: 2006 end-page: 208 article-title: Beta‐amlyoid 1‐42 and tau‐protein in cerebrospinal fluid of patients with Parkinson's disease dementia publication-title: Dement Geriatr Cogn Disord – volume: 57 start-page: 288 issue: 3 year: 2013 end-page: 291 article-title: Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD) publication-title: Arch Gerontol Geriatr – volume: 22 start-page: 1268 issue: 8 year: 2015 end-page: 1271 article-title: Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment publication-title: J Clin Neurosci – volume: 34 start-page: 2798 issue: 11 year: 2013 end-page: 2807 article-title: The topography of brain damage at different stages of Parkinson's disease publication-title: Hum Brain Mapp – volume: 36 start-page: 1659 issue: 4 year: 2015 end-page: 1669 article-title: Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease publication-title: Neurobiol Aging – volume: 85 start-page: 7 issue: 1 year: 2014 end-page: 16 article-title: Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 37 start-page: 276 issue: 5‐6 year: 2014 end-page: 285 article-title: Early diagnosis of Alzheimer's disease and Parkinson's disease associated with dementia using cerebral perfusion SPECT publication-title: Dement Geriatr Cogn Disord – volume: 124 start-page: 1970 issue: 10 year: 2013 end-page: 1974 article-title: Comparison of quantitative EEG between patients with Alzheimer's disease and those with Parkinson's disease dementia publication-title: Clin Neurophysiol – volume: 8 start-page: e54980 issue: 1 year: 2013 article-title: Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease publication-title: PLoS ONE – volume: 137 start-page: 2356 issue: Pt 8 year: 2014 end-page: 2367 article-title: Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two‐step process publication-title: Brain – volume: 19 start-page: 937 issue: 3 year: 2010 end-page: 942 article-title: The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease publication-title: J Alzheimers Dis – volume: 22 start-page: 553 issue: 2 year: 2004 end-page: 561 article-title: Cognitive‐ and motor‐related regions in Parkinson's disease: FDOPA and FDG PET studies publication-title: Neuroimage – volume: 36 start-page: 215 issue: 4 year: 1996 end-page: 220 article-title: Event‐related potentials in Parkinson's disease publication-title: Electromyogr Clin Neurophysiol – volume: 131 start-page: 397 issue: Pt 2 year: 2008 end-page: 408 article-title: Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype publication-title: Brain – volume: 129 start-page: 527 issue: 4 year: 2015 end-page: 540 article-title: Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease publication-title: Acta Neuropathol – volume: 25 start-page: 2550 issue: 15 year: 2010 end-page: 2554 article-title: Catechol‐O‐methyltransferase val158met and cognitive function in Parkinson's disease publication-title: Mov Disord – volume: 25 start-page: 2516 issue: 15 year: 2010 end-page: 2523 article-title: Amyloid imaging of Lewy body‐associated disorders publication-title: Mov Disord – volume: 11 start-page: 679 issue: 8 year: 2012 end-page: 687 article-title: Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross‐sectional study publication-title: Lancet Neurol – volume: 74 start-page: 419 issue: 4 year: 2003 end-page: 422 article-title: Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing publication-title: J Neurol Neurosurg Psychiatry – volume: 255 start-page: 1324 issue: 9 year: 2008 end-page: 1331 article-title: Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia publication-title: J Neurol – volume: 38 start-page: 938 issue: 6 year: 2013 end-page: 949 article-title: Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia publication-title: Neuropsychopharmacology – volume: 132 start-page: 3308 issue: Pt 12 year: 2009 end-page: 3317 article-title: Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia publication-title: Brain – volume: 70 start-page: 580 issue: 5 year: 2013 end-page: 586 article-title: Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study publication-title: JAMA Neurol – volume: 84 start-page: 1258 issue: 11 year: 2013 end-page: 1264 article-title: The CamPaIGN study of Parkinson's disease: 10‐year outlook in an incident population‐based cohort publication-title: J Neurol Neurosurg Psychiatry – volume: 37 start-page: 127 issue: 2 year: 2000 end-page: 152 article-title: Guidelines for using human event‐related potentials to study cognition: recording standards and publication criteria publication-title: Psychophysiology – volume: 32 start-page: 775 issue: 7 year: 2010 end-page: 779 article-title: Self‐report of cognitive impairment and mini‐mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease publication-title: J Clin Exp Neuropsychol – volume: 23 start-page: 837 issue: 6 year: 2008 end-page: 844 article-title: The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years publication-title: Mov Disord – volume: 119 start-page: 381 issue: 3 year: 2012 end-page: 382 article-title: Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease publication-title: J Neural Transm – volume: 7 start-page: 124 year: 2015 article-title: Microglial cell dysregulation in brain aging and neurodegeneration publication-title: Front Aging Neurosci – volume: 9 start-page: e110547 issue: 10 year: 2014 article-title: Neural substrates of cognitive subtypes in Parkinson's disease: a 3‐year longitudinal study publication-title: PLoS ONE – volume: 23 start-page: 1580 issue: 11 year: 2008 end-page: 1587 article-title: Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease publication-title: Mov Disord – volume: 5 start-page: 117 issue: 1 year: 2015 end-page: 124 article-title: Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease publication-title: J Parkinsons Dis – volume: 147 start-page: 1 issue: 1 year: 1999 end-page: 10 article-title: F(2)‐isoprostanes: sensitive and specific non‐invasive indices of lipid peroxidation in vivo publication-title: Atherosclerosis – volume: 6 start-page: 25 issue: 3 year: 2014 article-title: Levels of cerebrospinal fluid alpha‐synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease publication-title: Alzheimers Res Ther – volume: 62 start-page: 281 issue: 2 year: 2005 end-page: 285 article-title: Structural brain changes in Parkinson disease with dementia: a voxel‐based morphometry study publication-title: Arch Neurol – volume: 85 start-page: 576 issue: 5 year: 2014 end-page: 580 article-title: Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy publication-title: J Neurol Neurosurg Psychiatry – volume: 5 start-page: 37 issue: 1‐2 year: 1999 end-page: 41 article-title: Electroencephalography of demented and non‐demented Parkinson's disease patients publication-title: Parkinsonism Relat Disord – volume: 132 start-page: 2958 issue: Pt 11 year: 2009 end-page: 2969 article-title: The distinct cognitive syndromes of Parkinson's disease: 5 year follow‐up of the CamPaIGN cohort publication-title: Brain – volume: 468 start-page: 56 issue: 1 year: 2010 end-page: 58 article-title: Serum levels of interleukin‐6 are elevated in patients with Parkinson's disease and correlate with physical performance publication-title: Neurosci Lett – volume: 22 start-page: 166 issue: 3 year: 2009 end-page: 170 article-title: APOE alleles in Parkinson disease and their relationship to cognitive decline: a population‐based, longitudinal study publication-title: J Geriatr Psychiatry Neurol – volume: 35 start-page: 4620 issue: 9 year: 2014 end-page: 4634 article-title: Functional brain networks and cognitive deficits in Parkinson's disease publication-title: Hum Brain Mapp – volume: 20 start-page: 1076 issue: 10 year: 2014 end-page: 1080 article-title: Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates publication-title: Parkinsonism Relat Disord – volume: 6 start-page: 131 issue: 3 year: 1993 end-page: 136 article-title: P300 and reaction time in Parkinson's disease publication-title: J Geriatr Psychiatry Neurol – volume: 29 start-page: 360 issue: 3 year: 2014 end-page: 367 article-title: Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease publication-title: Mov Disord – volume: 84 start-page: 1318 issue: 7 year: 2015 end-page: 1324 article-title: Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status publication-title: Eur J Radiol – volume: 25 start-page: 2682 issue: 15 year: 2010 end-page: 2685 article-title: CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment publication-title: Mov Disord – volume: 138 start-page: 2974 issue: Pt 10 year: 2015 end-page: 2986 article-title: Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE‐PD study publication-title: Brain – volume: 18 start-page: 784 issue: 7 year: 2003 end-page: 790 article-title: Parkinson's disease is associated with hippocampal atrophy publication-title: Mov Disord – volume: 60 start-page: 1745 issue: 12 year: 2003 end-page: 1748 article-title: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study publication-title: Arch Neurol – volume: 24 start-page: 392 issue: 3 year: 2009 end-page: 400 article-title: BuChE‐K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline publication-title: Mov Disord – volume: 31 start-page: 103 issue: 1 year: 2016 end-page: 110 article-title: Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease? publication-title: Mov Disord – volume: 13 start-page: 174 issue: 3 year: 2007 end-page: 181 article-title: Heterogeneous factors in dementia with Parkinson's disease: IMP‐SPECT study publication-title: Parkinsonism Relat Disord – volume: 75 start-page: 1055 issue: 12 year: 2010 end-page: 1061 article-title: CSF amyloid {beta} 1‐42 predicts cognitive decline in Parkinson disease publication-title: Neurology – volume: 260 start-page: 438 issue: 2 year: 2013 end-page: 444 article-title: Serum epidermal growth factor predicts cognitive functions in early, drug‐naive Parkinson's disease patients publication-title: J Neurol – volume: 73 start-page: 273 issue: 4 year: 2009 end-page: 278 article-title: Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET publication-title: Neurology – volume: 137 start-page: 2743 issue: Pt 10 year: 2014 end-page: 2758 article-title: Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE‐PD study publication-title: Brain – volume: 72 start-page: 587 issue: 4 year: 2012 end-page: 598 article-title: Neuropathologic substrates of Parkinson disease dementia publication-title: Ann Neurol – volume: 27 start-page: 119 issue: 1 year: 2011 end-page: 126 article-title: Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid‐beta pathway publication-title: J Alzheimers Dis – volume: 414 start-page: 141 issue: 2 year: 2007 end-page: 144 article-title: Phenotypic associations of tau and ApoE in Parkinson's disease publication-title: Neurosci Lett – volume: 60 start-page: 387 issue: 3 year: 2003 end-page: 392 article-title: Prevalence and characteristics of dementia in Parkinson disease: an 8‐year prospective study publication-title: Arch Neurol – volume: 64 start-page: 850 issue: 10 year: 2008 end-page: 855 article-title: Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies publication-title: Biol Psychiatry – volume: 20 start-page: 989 issue: 8 year: 2005 end-page: 994 article-title: Apolipoprotein E epsilon4 and catechol‐O‐methyltransferase alleles in autopsy‐proven Parkinson's disease: relationship to dementia and hallucinations publication-title: Mov Disord – volume: 1 start-page: 884 issue: 11 year: 2014 end-page: 890 article-title: Power spectra for screening parkinsonian patients for mild cognitive impairment publication-title: Ann Clin Transl Neurol – volume: 34 start-page: 107 issue: 1 year: 2009 end-page: 112 article-title: Cortical PIB binding in Lewy body disease is associated with Alzheimer‐like characteristics publication-title: Neurobiol Dis – volume: 81 start-page: 520 issue: 6 year: 2013 end-page: 527 article-title: Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases publication-title: Neurology – volume: 27 start-page: 965 issue: 8 year: 2012 end-page: 973 article-title: Brain amyloid and cognition in Lewy body diseases publication-title: Mov Disord – volume: 27 start-page: 512 issue: 4 year: 2012 end-page: 518 article-title: Genetic influences on cognitive decline in Parkinson's disease publication-title: Mov Disord – volume: 22 start-page: 45 issue: 1 year: 2001 end-page: 46 article-title: Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease publication-title: Neurol Sci – volume: 64 start-page: 261 issue: 2 year: 2007 end-page: 265 article-title: Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia publication-title: Arch Neurol – volume: 64 start-page: 224 issue: 2 year: 2005 end-page: 229 article-title: Cerebral atrophy and its relation to cognitive impairment in Parkinson disease publication-title: Neurology – volume: 43 start-page: 967 issue: 6 year: 2005 end-page: 975 article-title: Event‐related potentials for response inhibition in Parkinson's disease publication-title: Neuropsychologia – volume: 20 start-page: 1203 issue: 11 year: 2014 end-page: 1208 article-title: Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 137 start-page: 565 issue: Pt 2 year: 2014 end-page: 575 article-title: Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment publication-title: Brain – volume: 561 start-page: 86 year: 2014 end-page: 90 article-title: BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease publication-title: Neurosci Lett – volume: 39 start-page: 1027 issue: 3 year: 2008 end-page: 1033 article-title: [11C]PIB binding in Parkinson's disease dementia publication-title: Neuroimage – volume: 64 start-page: 861 issue: 5 year: 2005 end-page: 865 article-title: Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies publication-title: Neurology – volume: 248 start-page: 68 issue: 1‐2 year: 2006 end-page: 71 article-title: Putamen FDOPA uptake and its relationship tot cognitive functioning in PD publication-title: J Neurol Sci – volume: 7 start-page: e993266 issue: 6 year: 2014 article-title: Lipid disequilibrium in biological membranes, a possible pathway to neurodegeneration publication-title: Commun Integr Biol – volume: 19 start-page: 717 issue: 8 year: 2013 end-page: 724 article-title: Combined dementia‐risk biomarkers in Parkinson's disease: a prospective longitudinal study publication-title: Parkinsonism Relat Disord – volume: 26 start-page: 218 issue: 3 year: 2008 end-page: 225 article-title: A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia publication-title: Dement Geriatr Cogn Disord – volume: 16 start-page: 666 issue: 10 year: 2010 end-page: 670 article-title: [(11)C]PIB‐, [(18)F]FDG‐PET and MRI imaging in patients with Parkinson's disease with and without dementia publication-title: Parkinsonism Relat Disord – volume: 116 start-page: 193 issue: 2 year: 2009 end-page: 202 article-title: MEG resting state functional connectivity in Parkinson's disease related dementia publication-title: J Neural Transm – volume: 20 start-page: 772 issue: 7 year: 2014 end-page: 775 article-title: Is serum uric acid related to non‐motor symptoms in de‐novo Parkinson's disease patients? publication-title: Parkinsonism Relat Disord – volume: 27 start-page: 1262 issue: 10 year: 2012 end-page: 1267 article-title: Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease publication-title: Mov Disord – volume: 22 start-page: 446 issue: 3 year: 2010 end-page: 449 article-title: Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment publication-title: Psychiatr Danub – volume: 20 start-page: 1405 issue: 12 year: 2014 end-page: 1410 article-title: Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 24 start-page: 176 issue: 2 year: 2009 end-page: 182 article-title: Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients publication-title: Mov Disord – volume: 343 start-page: 120 issue: 1‐2 year: 2014 end-page: 124 article-title: Tau protein, beta‐amyloid(1)(‐)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia publication-title: J Neurol Sci – volume: 45 start-page: 511 issue: 8 year: 2013 end-page: 521 article-title: Glucocerebrosidase mutations and the pathogenesis of Parkinson disease publication-title: Ann Med – volume: 30 start-page: 928 issue: 7 year: 2015 end-page: 935 article-title: Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review publication-title: Mov Disord – volume: 21 start-page: 1343 issue: 9 year: 2006 end-page: 1349 article-title: Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia publication-title: Mov Disord – volume: 2014 start-page: 903796 year: 2014 article-title: Cognitive status correlates with CXCL10/IP‐10 levels in Parkinson's disease publication-title: Parkinsons Dis – volume: 19 start-page: 329 issue: 3 year: 2013 end-page: 334 article-title: Marked N‐acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment publication-title: Parkinsonism Relat Disord – volume: 25 start-page: 35 issue: 1 year: 2010 end-page: 43 article-title: Cognitive‐nigrostriatal relationships in de novo, drug‐naive Parkinson's disease patients: a [I‐123]FP‐CIT SPECT study publication-title: Mov Disord – volume: 80 start-page: 1841 issue: 20 year: 2013 end-page: 1849 article-title: White matter microstructure deteriorates across cognitive stages in Parkinson disease publication-title: Neurology – volume: 66 start-page: 866 issue: 8 year: 2009 end-page: 877 article-title: Reduced alpha4beta2*‐nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease publication-title: Arch Gen Psychiatry – volume: 8 start-page: e73094 issue: 9 year: 2013 article-title: Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study publication-title: PLoS ONE – volume: 22 start-page: 54 issue: 1 year: 2008 end-page: 60 article-title: Brain N‐acetylaspartate is reduced in Parkinson disease with dementia publication-title: Alzheimer Dis Assoc Disord – volume: 84 start-page: 875 issue: 8 year: 2013 end-page: 881 article-title: Cortical thinning is associated with disease stages and dementia in Parkinson's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 74 start-page: 885 issue: 11 year: 2010 end-page: 892 article-title: Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo publication-title: Neurology – volume: 32 start-page: 1609 issue: 8 year: 2012 end-page: 1617 article-title: Heterogeneity of cholinergic denervation in Parkinson's disease without dementia publication-title: J Cereb Blood Flow Metab – volume: 34 start-page: 714 issue: 2 year: 2007 end-page: 723 article-title: Metabolic brain networks associated with cognitive function in Parkinson's disease publication-title: Neuroimage – year: 2014 article-title: Presence and progression of non‐motor symptoms in relation to uric acid in de novo Parkinson's disease publication-title: Eur J Neurol – volume: 117 start-page: 2521 issue: 11 year: 2006 end-page: 2531 article-title: Resting state oscillatory brain dynamics in Parkinson's disease: an MEG study publication-title: Clin Neurophysiol – volume: 25 start-page: 361 issue: 6 year: 2008 end-page: 366 article-title: Comparison of quantitative EEGs between Parkinson disease and age‐adjusted normal controls publication-title: J Clin Neurophysiol – volume: 147 start-page: 403 issue: 3 year: 2008 end-page: 407 article-title: Alpha‐synuclein promoter haplotypes and dementia in Parkinson's disease publication-title: Am J Med Genet B Neuropsychiatr Genet – volume: 19 start-page: 266 issue: 5‐6 year: 2005 end-page: 275 article-title: Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three‐dimensional stereotactic surface projection imaging publication-title: Dement Geriatr Cogn Disord – volume: 130 start-page: 164 issue: 3 year: 2014 end-page: 171 article-title: Nicotinic alpha4beta2 acetylcholine receptors and cognitive function in Parkinson's disease publication-title: Acta Neurol Scand – volume: 36 start-page: 476 issue: 1 year: 2015 end-page: 484 article-title: Correlation between decreased CSF alpha‐synuclein and Abeta(1)(‐)(4)(2) in Parkinson disease publication-title: Neurobiol Aging – volume: 262 start-page: 294 issue: 2 year: 2015 end-page: 306 article-title: Correlates of cerebrospinal fluid levels of oligomeric‐ and total‐alpha‐synuclein in premotor, motor and dementia stages of Parkinson's disease publication-title: J Neurol – volume: 21 start-page: 802 issue: 5 year: 2014 end-page: 807 article-title: Insulin‐like growth factor‐1 predicts cognitive functions at 2‐year follow‐up in early, drug‐naive Parkinson's disease publication-title: Eur J Neurol – volume: 23 start-page: 998 issue: 7 year: 2008 end-page: 1005 article-title: Parkinson's disease‐cognitive rating scale: a new cognitive scale specific for Parkinson's disease publication-title: Mov Disord – volume: 38 start-page: 315 issue: 5 year: 2013 end-page: 320 article-title: Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT publication-title: Clin Nucl Med – volume: 29 start-page: 1802 issue: 14 year: 2014 end-page: 1808 article-title: Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease publication-title: Mov Disord – volume: 213 start-page: 92 issue: 2 year: 2013 end-page: 98 article-title: Predicting dementia development in Parkinson's disease using Bayesian network classifiers publication-title: Psychiatry Res – volume: 74 start-page: 77 issue: 1 year: 2010 end-page: 84 article-title: In vivo amyloid imaging in autopsy‐confirmed Parkinson disease with dementia publication-title: Neurology – volume: 35 start-page: 183 issue: 3‐4 year: 2013 end-page: 196 article-title: Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study publication-title: Dement Geriatr Cogn Disord – volume: 448 start-page: 20 issue: 1 year: 2008 end-page: 23 article-title: Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease publication-title: Neurosci Lett – volume: 7 start-page: e48783 issue: 11 year: 2012 article-title: Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia publication-title: PLoS ONE – volume: 71 start-page: 1405 issue: 11 year: 2014 end-page: 1412 article-title: APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease publication-title: JAMA Neurol – volume: 33 start-page: 1265 issue: 7 year: 2012 end-page: 1272 article-title: Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status publication-title: Neurobiol Aging – volume: 10 start-page: 232 issue: 1‐4 year: 2012 end-page: 237 article-title: Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia publication-title: Neurodegener Dis – volume: 116 start-page: 347 issue: 6 year: 2007 end-page: 354 article-title: Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease—a rCBF scintigraphy study publication-title: Acta Neurol Scand – volume: 23 start-page: 295 issue: 3 year: 2009 end-page: 297 article-title: Parkinson disease with dementia: comparing patients with and without Alzheimer pathology publication-title: Alzheimer Dis Assoc Disord – volume: 45 start-page: 667 issue: 3 year: 1991 end-page: 670 article-title: Event‐related potentials in senile dementia of Alzheimer's type, multiinfarct dementia and Parkinson's disease publication-title: Jpn J Psychiatry Neurol – volume: 28 start-page: 302 issue: 3 year: 2013 end-page: 310 article-title: Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson's disease publication-title: Mov Disord – volume: 22 start-page: 236 issue: 3 year: 2004 end-page: 245 article-title: Executive processes in Parkinson's disease: FDG‐PET and network analysis publication-title: Hum Brain Mapp – volume: 263 start-page: 226 issue: 1 year: 2012 end-page: 234 article-title: Interregional correlations in Parkinson disease and Parkinson‐related dementia with resting functional MR imaging publication-title: Radiology – volume: 310 start-page: 86 issue: 1‐2 year: 2011 end-page: 89 article-title: Initial neuropsychological impairments in patients with the E46K mutation of the alpha‐synuclein gene (PARK 1) publication-title: J Neurol Sci – volume: 25 start-page: 687 issue: 6 year: 2010 end-page: 695 article-title: Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia publication-title: Mov Disord – volume: 72 start-page: 1175 issue: 10 year: 2015 end-page: 1182 article-title: Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson Disease publication-title: JAMA Neurol – volume: 9 start-page: 92 issue: 1 year: 1994 end-page: 97 article-title: Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study publication-title: Mov Disord – volume: 68 start-page: 359 issue: 3 year: 2011 end-page: 364 article-title: Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes publication-title: Arch Neurol – volume: 62 start-page: 145 issue: 2 year: 2007 end-page: 153 article-title: Tau and alpha‐synuclein in susceptibility to, and dementia in, Parkinson's disease publication-title: Ann Neurol – volume: 234 start-page: 499 issue: 2 year: 2012 end-page: 505 article-title: iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia publication-title: Exp Neurol – volume: 78 start-page: 254 issue: 3 year: 2007 end-page: 259 article-title: A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel‐based morphometry publication-title: J Neurol Neurosurg Psychiatry – volume: 33 start-page: 727 issue: 3 year: 2012 end-page: 739 article-title: Cognitive status correlates with white matter alteration in Parkinson's disease publication-title: Hum Brain Mapp – volume: 21 start-page: 758 issue: 7 year: 2015 end-page: 764 article-title: Amyloid‐beta and alpha‐synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 53 start-page: S26 issue: suppl 3 year: 2003 end-page: S36 article-title: Oxidative stress in Parkinson's disease publication-title: Ann Neurol – volume: 21 start-page: 899 issue: 8 year: 2015 end-page: 904 article-title: Cognitive reserve and beta‐amyloid pathology in Parkinson disease publication-title: Parkinsonism Relat Disord – volume: 479 start-page: 123 issue: 2 year: 2010 end-page: 125 article-title: Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease publication-title: Neurosci Lett – volume: 82 start-page: 2017 issue: 22 year: 2014 end-page: 2025 article-title: Initial cognitive decline is associated with cortical thinning in early Parkinson disease publication-title: Neurology – volume: 116 start-page: 177 issue: 3 year: 2007 end-page: 181 article-title: Dementia in Parkinson's disease: diffusion tensor imaging publication-title: Acta Neurol Scand – volume: 131 start-page: 690 issue: Pt 3 year: 2008 end-page: 705 article-title: EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2‐year follow‐up publication-title: Brain – volume: 20 start-page: 262 issue: 2 year: 2014 end-page: 264 article-title: Clinical and neuroimaging features of patient with early‐onset Parkinson's disease with dementia carrying SNCA p.G51D mutation publication-title: Parkinsonism Relat Disord – volume: 18 start-page: 941 issue: 8 year: 2012 end-page: 947 article-title: Grey matter volume correlates of cerebrospinal markers of Alzheimer‐pathology in Parkinson's disease and related dementia publication-title: Parkinsonism Relat Disord – volume: 9 start-page: 197 issue: 2‐3 year: 1995 end-page: 209 article-title: Modality dependent changes in event‐related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease publication-title: J Neural Transm Park Dis Dement Sect – volume: 35 start-page: 223 issue: 1 year: 2014 end-page: 231 article-title: Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease publication-title: Neurobiol Aging – volume: 123 start-page: 340 issue: Pt 2 year: 2000 end-page: 352 article-title: Cortical dysfunction in non‐demented Parkinson's disease patients: a combined (31)P‐MRS and (18)FDG‐PET study publication-title: Brain – volume: 14 start-page: 113 issue: 1 year: 2014 article-title: Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross‐sectional study publication-title: BMC Neurol – volume: 311 start-page: 81 issue: 2 year: 2001 end-page: 84 article-title: Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus publication-title: Neurosci Lett – volume: 406 start-page: 235 issue: 3 year: 2006 end-page: 239 article-title: Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease publication-title: Neurosci Lett – volume: 15 start-page: 88 issue: 2 year: 2009 end-page: 93 article-title: Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy publication-title: Parkinsonism Relat Disord – volume: 14 start-page: 576 issue: 7 year: 2008 end-page: 578 article-title: Uric acid associates with cognition in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 30 start-page: 1162 issue: 6 year: 2009 end-page: 1171 article-title: Neuroanatomical correlates of impaired decision‐making and facial emotion recognition in early Parkinson's disease publication-title: Eur J Neurosci – volume: 81 start-page: 1080 issue: 10 year: 2010 end-page: 1086 article-title: CSF amyloid‐beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study publication-title: J Neurol Neurosurg Psychiatry – volume: 40 start-page: 399 issue: 3 year: 1996 end-page: 410 article-title: In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease publication-title: Ann Neurol – volume: 39 start-page: 207 issue: 3‐4 year: 2015 end-page: 214 article-title: Correlation of EEG slowing with cognitive domains in nondemented patients with Parkinson's disease publication-title: Dement Geriatr Cogn Disord – volume: 4 start-page: 68 issue: 2 year: 2011 end-page: 72 article-title: Analysis of the substantia innominata volume in patients with Parkinson's disease with dementia, dementia with lewy bodies, and Alzheimer's disease publication-title: J Mov Disord – volume: 107 start-page: 396 issue: 5 year: 2005 end-page: 403 article-title: Brain 3D‐SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease publication-title: Clin Neurol Neurosurg – volume: 39 start-page: 228 issue: 4 year: 1993 end-page: 240 article-title: Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison publication-title: Gerontology – volume: 16 start-page: 1240 issue: 11 year: 2009 end-page: 1245 article-title: BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease publication-title: Eur J Neurol – volume: 541 start-page: 111 year: 2013 end-page: 115 article-title: Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population publication-title: Neurosci Lett – volume: 310 start-page: 75 issue: 1‐2 year: 2011 end-page: 78 article-title: Clinical EEG in cognitively impaired patients with Parkinson's Disease publication-title: J Neurol Sci – volume: 25 start-page: 28 issue: 1 year: 2010 end-page: 34 article-title: A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel‐based morphometry publication-title: Mov Disord – volume: 13 start-page: 348 issue: 6 year: 2007 end-page: 354 article-title: Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 487 start-page: 169 issue: 2 year: 2011 end-page: 173 article-title: High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta‐amyloid in Parkinson disease publication-title: Neurosci Lett – volume: 113 start-page: 14 issue: 1 year: 2006 end-page: 17 article-title: Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease publication-title: Acta Neurol Scand – volume: 253 start-page: 242 issue: 2 year: 2006 end-page: 247 article-title: Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia publication-title: J Neurol – volume: 2 start-page: 249 issue: 4 year: 1990 end-page: 264 article-title: The auditory P 300 correlates with specific cognitive deficits in Parkinson's disease publication-title: J Neural Transm Park Dis Dement Sect – volume: 28 start-page: 1285 issue: 9 year: 2013 end-page: 1288 article-title: Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease? publication-title: Mov Disord – volume: 20 start-page: 637 issue: 6 year: 2014 end-page: 639 article-title: Serum uric acid and risk of dementia in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 20 start-page: 540 issue: 5 year: 2005 end-page: 544 article-title: Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia publication-title: Mov Disord – volume: 59 start-page: 1415 issue: 9 year: 2002 end-page: 1420 article-title: Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study publication-title: Arch Neurol – volume: 35 start-page: 1325 issue: 4 year: 2014 end-page: 1333 article-title: DTI correlates of distinct cognitive impairments in Parkinson's disease publication-title: Hum Brain Mapp – volume: 166 start-page: 141 issue: 2 year: 1999 end-page: 151 article-title: The relation of putamen and caudate nucleus 18F‐Dopa uptake to motor and cognitive performances in Parkinson's disease publication-title: J Neurol Sci – volume: 72 start-page: 194 issue: 2 year: 2015 end-page: 200 article-title: Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects publication-title: JAMA Neurol – volume: 351 start-page: 1105 issue: 9109 year: 1998 end-page: 1106 article-title: Cerebrospinal‐fluid tau protein and aspartate aminotransferase in Parkinson's disease publication-title: Lancet – volume: 55 start-page: 960 issue: 10 year: 1992 end-page: 963 article-title: SPECT findings in Parkinson's disease associated with dementia publication-title: J Neurol Neurosurg Psychiatry – volume: 6 start-page: 53 year: 2014 article-title: Differential role of CSF alpha‐synuclein species, tau, and Abeta42 in Parkinson's Disease publication-title: Front Aging Neurosci – volume: 20 start-page: 503 issue: 5 year: 2014 end-page: 507 article-title: Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status publication-title: Parkinsonism Relat Disord – volume: 44 start-page: 1046 issue: 10 year: 2005 end-page: 1050 article-title: N‐isopropyl‐p‐ 123I iodoamphetamine single photon emission computed tomography study of Parkinson's disease with dementia publication-title: Intern Med – volume: 29 start-page: 305 issue: 6 year: 2006 end-page: 311 article-title: Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima‐media thickness and neuropsychiatric complications publication-title: Clin Neuropharmacol – volume: 15 start-page: 187 issue: 3 year: 2009 end-page: 195 article-title: Voxel‐based morphometry reveals extra‐nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism publication-title: Parkinsonism Relat Disord – volume: 83 start-page: 2046 issue: 22 year: 2014 end-page: 2053 article-title: Functional connectivity and cognitive decline over 3 years in Parkinson disease publication-title: Neurology – volume: 23 start-page: 1946 issue: 7 year: 2013 end-page: 1955 article-title: Relationship between cognitive impairment and white‐matter alteration in Parkinson's disease with dementia: tract‐based spatial statistics and tract‐specific analysis publication-title: Eur Radiol – volume: 3 start-page: 547 issue: 4 year: 2013 end-page: 555 article-title: Memory, mood, and vitamin d in persons with Parkinson's disease publication-title: J Parkinsons Dis – volume: 69 start-page: 1445 issue: 11 year: 2012 end-page: 1452 article-title: Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders publication-title: Arch Neurol – volume: 136 start-page: 392 issue: Pt 2 year: 2013 end-page: 399 article-title: Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community‐based incident cohort publication-title: Brain – volume: 78 start-page: 1 issue: 1 year: 1988 end-page: 5 article-title: EEG in demented and non‐demented parkinsonian patients publication-title: Acta Neurol Scand – volume: 26 start-page: 289 issue: 2 year: 2011 end-page: 296 article-title: The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status publication-title: Mov Disord – volume: 52 start-page: 848 issue: 6 year: 2011 end-page: 855 article-title: Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study publication-title: J Nucl Med – volume: 27 start-page: 51 issue: 1 year: 2013 end-page: 55 article-title: An FP‐CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia publication-title: Alzheimer Dis Assoc Disord – volume: 33 start-page: 890 issue: 5 year: 2012 end-page: 895 article-title: White matter alteration of the cingulum in Parkinson disease with and without dementia: evaluation by diffusion tensor tract‐specific analysis publication-title: Am J Neuroradiol – volume: 70 start-page: 1470 issue: 16 Pt 2 year: 2008 end-page: 1477 article-title: Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease publication-title: Neurology – volume: 28 start-page: 384 issue: 4 year: 2011 end-page: 387 article-title: Relationship between slowing of the EEG and cognitive impairment in Parkinson disease publication-title: J Clin Neurophysiol – volume: 37 start-page: 242 issue: 2 year: 1995 end-page: 245 article-title: Apolipoprotein E genotypes in Parkinson's disease with and without dementia publication-title: Ann Neurol – volume: 256 start-page: 493 issue: 3 year: 2009 end-page: 498 article-title: Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease publication-title: J Neurol – volume: 30 start-page: 407 issue: 3 year: 2015 end-page: 411 article-title: GBA‐associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study publication-title: Mov Disord – volume: 78 start-page: 1434 issue: 18 year: 2012 end-page: 1440 article-title: Cognitive performance of GBA mutation carriers with early‐onset PD: the CORE‐PD study publication-title: Neurology – volume: 27 start-page: 4832 issue: 18 year: 2007 end-page: 4838 article-title: Catechol O‐methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease publication-title: J Neurosci – volume: 21 start-page: 45 issue: 1 year: 2006 end-page: 49 article-title: Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia publication-title: Mov Disord – volume: 28 start-page: 169 issue: 2 year: 2013 end-page: 175 article-title: beta‐Amyloid in Lewy body disease is related to Alzheimer's disease‐like atrophy publication-title: Mov Disord – volume: 8 start-page: e64222 issue: 5 year: 2013 article-title: Anatomical correlates of cognitive functions in early Parkinson's disease patients publication-title: PLoS ONE – volume: 24 start-page: 2203 issue: 15 year: 2009 end-page: 2210 article-title: Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease publication-title: Mov Disord – volume: 52 start-page: 1787 issue: 16 year: 2013 end-page: 1792 article-title: Is neuroinflammation involved in the development of dementia in patients with Parkinson's disease? publication-title: Intern Med – volume: 77 start-page: 269 issue: 2 year: 2015 end-page: 280 article-title: Salience network and parahippocampal dopamine dysfunction in memory‐impaired Parkinson disease publication-title: Ann Neurol – volume: 21 start-page: 456 issue: 4 year: 2006 end-page: 461 article-title: Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study publication-title: Mov Disord – volume: 26 start-page: 1814 issue: 10 year: 2011 end-page: 1824 article-title: MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD‐MCI publication-title: Mov Disord – volume: 64 start-page: 1404 issue: 8 year: 2005 end-page: 1410 article-title: Cognitive status correlates with neuropathologic stage in Parkinson disease publication-title: Neurology – volume: 24 start-page: 414 issue: 3 year: 2009 end-page: 421 article-title: Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study publication-title: Mov Disord – volume: 220 start-page: 2249 issue: 4 year: 2015 end-page: 2261 article-title: Imaging changes associated with cognitive abnormalities in Parkinson's disease publication-title: Brain Struct Funct – volume: 79 start-page: 1331 issue: 12 year: 2008 end-page: 1338 article-title: Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography publication-title: J Neurol Neurosurg Psychiatry – volume: 24 start-page: 1811 issue: 12 year: 2009 end-page: 1819 article-title: Expanding the clinical phenotype of SNCA duplication carriers publication-title: Mov Disord – volume: 24 start-page: 1437 issue: 10 year: 2009 end-page: 1444 article-title: Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study publication-title: Mov Disord – volume: 55 start-page: 174 issue: 2 year: 2004 end-page: 179 article-title: Comparison of kindreds with parkinsonism and alpha‐synuclein genomic multiplications publication-title: Ann Neurol – volume: 9 start-page: 130 year: 2015 article-title: A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease publication-title: Front Hum Neurosci – volume: 8 start-page: 45 year: 2014 article-title: Large‐scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits publication-title: Front Syst Neurosci – volume: 8 start-page: 207 year: 2014 article-title: Longitudinal changes in task‐evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment publication-title: Front Neurosci – volume: 79 start-page: 159 issue: 3 year: 1991 end-page: 165 article-title: Slowing of EEG in Parkinson's disease publication-title: Electroencephalogr Clin Neurophysiol – volume: 69 start-page: 655 issue: 4 year: 2011 end-page: 663 article-title: Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease publication-title: Ann Neurol – volume: 121 start-page: 139 issue: 2 year: 1994 end-page: 146 article-title: Somatosensory event‐related potentials (ERPs) in patients with different types of dementia publication-title: J Neurol Sci – volume: 46 start-page: 817 issue: 10 year: 2004 end-page: 821 article-title: Substantia innominata: MR findings in Parkinson's disease publication-title: Neuroradiology – volume: 8 start-page: e53250 issue: 1 year: 2013 article-title: Low CSF levels of both alpha‐synuclein and the alpha‐synuclein cleaving enzyme neurosin in patients with synucleinopathy publication-title: PLoS ONE – volume: 23 start-page: 6351 issue: 15 year: 2003 end-page: 6356 article-title: Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry publication-title: J Neurosci – volume: 64 start-page: 65 issue: 2 year: 2010 end-page: 73 article-title: Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment publication-title: Eur Neurol – volume: 29 start-page: 634 issue: 5 year: 2014 end-page: 650 article-title: The neurobiological basis of cognitive impairment in Parkinson's disease publication-title: Mov Disord – volume: 131 start-page: 275 issue: 5 year: 2015 end-page: 281 article-title: Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study publication-title: Acta Neurol Scand – volume: 72 start-page: 1487 issue: 17 year: 2009 end-page: 1494 article-title: Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease publication-title: Neurology – volume: 36 start-page: 2980 issue: 8 year: 2015 end-page: 2995 article-title: Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease publication-title: Hum Brain Mapp – volume: 77 start-page: 1357 issue: 14 year: 2011 end-page: 1362 article-title: Mild cognitive impairment in drug‐naive patients with PD is associated with cerebral hypometabolism publication-title: Neurology – volume: 4 start-page: 37 year: 2013 article-title: White‐matter changes correlate with cognitive functioning in Parkinson's disease publication-title: Front Neurol – volume: 125 start-page: 1358 issue: Pt 6 year: 2002 end-page: 1365 article-title: Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6‐[18F]fluoro‐L‐dopa PET study publication-title: Brain – volume: 32 start-page: 1176 issue: 10 year: 2005 end-page: 1185 article-title: Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I‐FP‐CIT SPECT publication-title: Eur J Nucl Med Mol Imaging – volume: 75 start-page: 1467 issue: 10 year: 2004 end-page: 1469 article-title: Hippocampal and prefrontal atrophy in patients with early non‐demented Parkinson's disease is related to cognitive impairment publication-title: J Neurol Neurosurg Psychiatry – volume: 20 start-page: 999 issue: 8 year: 2005 end-page: 1005 article-title: Three‐dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia publication-title: Mov Disord – volume: 21 start-page: 271 issue: 3 year: 2015 end-page: 276 article-title: CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 28 start-page: 1360 issue: 10 year: 2013 end-page: 1369 article-title: Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration publication-title: Mov Disord – volume: 27 start-page: 193 issue: 3 year: 2010 end-page: 197 article-title: Quantitative EEG analysis of executive dysfunction in Parkinson disease publication-title: J Clin Neurophysiol – volume: 248 start-page: 62 issue: 1‐2 year: 2006 end-page: 67 article-title: Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease publication-title: J Neurol Sci – volume: 13 start-page: 744 issue: 10 year: 1992 end-page: 748 article-title: Cognition and 99Tcm‐HMPAO SPECT in Parkinson's disease publication-title: Nucl Med Commun – volume: 7 start-page: 109 issue: 2 year: 1994 end-page: 114 article-title: Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy publication-title: J Neural Transm Park Dis Dement Sect – volume: 77 start-page: 118 issue: 2 year: 2011 end-page: 124 article-title: Quantitative EEG as a predictive biomarker for Parkinson disease dementia publication-title: Neurology – volume: 33 start-page: 183 year: 2013 end-page: 189 article-title: Cerebrospinal fluid inflammatory markers in Parkinson's disease—associations with depression, fatigue, and cognitive impairment publication-title: Brain Behav Immun – volume: 24 start-page: 854 issue: 6 year: 2009 end-page: 862 article-title: Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment publication-title: Mov Disord – volume: 127 start-page: 791 issue: Pt 4 year: 2004 end-page: 800 article-title: Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls publication-title: Brain – volume: 68 start-page: 1562 issue: 12 year: 2011 end-page: 1568 article-title: Neurodegeneration across stages of cognitive decline in Parkinson disease publication-title: Arch Neurol – volume: 17 start-page: 61 issue: 1 year: 2011 end-page: 64 article-title: Cerebrospinal fluid biomarkers and cognitive performance in non‐demented patients with Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 36 start-page: 1519 issue: 3 year: 2015 end-page: 1528 article-title: Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals publication-title: Neurobiol Aging – volume: 93 start-page: 251 issue: 5‐6 year: 2015 end-page: 256 article-title: Plasma insulin‐like growth factor 1 is associated with cognitive impairment in Parkinson's disease publication-title: Dement Geriatr Cogn Disord – volume: 184 start-page: 966 issue: 4 year: 2014 end-page: 975 article-title: Cerebrospinal fluid alpha‐synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort publication-title: Am J Pathol – volume: 14 start-page: 1357 issue: 12 year: 2007 end-page: 1362 article-title: A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies publication-title: Eur J Neurol – volume: 79 start-page: 458 issue: 3 year: 2002 end-page: 461 article-title: Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset publication-title: Genomics – volume: 28 start-page: 154 issue: 2 year: 2013 end-page: 164 article-title: Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson's disease publication-title: Am J Alzheimers Dis Other Demen – volume: 36 start-page: 1851 issue: 11 year: 2009 end-page: 1858 article-title: Neuropsychological functions and rCBF SPECT in Parkinson's disease patients considered candidates for deep brain stimulation publication-title: Eur J Nucl Med Mol Imaging – volume: 347 start-page: 210 issue: 1‐2 year: 2014 end-page: 213 article-title: Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive impairment publication-title: J Neurol Sci – volume: 39 start-page: 1767 issue: 11 year: 2012 end-page: 1777 article-title: Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease publication-title: Eur J Nucl Med Mol Imaging – volume: 42 start-page: S217 issue: suppl 3 year: 2014 end-page: S228 article-title: Default mode network connectivity patterns associated with visual processing at different stages of Parkinson's disease publication-title: J Alzheimers Dis – volume: 11 start-page: 39 issue: 1 year: 2000 end-page: 45 article-title: Event‐related potential and EEG measures in Parkinson's disease without and with dementia publication-title: Dement Geriatr Cogn Disord – volume: 81 start-page: 346 issue: 4 year: 2013 end-page: 352 article-title: Evolution of mild cognitive impairment in Parkinson disease publication-title: Neurology – volume: 27 start-page: 1052 issue: 8 year: 2012 end-page: 1055 article-title: Short latency afferent inhibition in Parkinson's disease patients with dementia publication-title: Mov Disord – volume: 134 start-page: 1493 issue: Pt 5 year: 2011 end-page: 1505 article-title: Lewy‐ and Alzheimer‐type pathologies in Parkinson's disease dementia: which is more important? publication-title: Brain – volume: 58 start-page: 773 issue: 5 year: 2005 end-page: 776 article-title: Neuropathology of dementia in Parkinson's disease: a prospective, community‐based study publication-title: Ann Neurol – volume: 61 start-page: 865 issue: 6 year: 2004 end-page: 868 article-title: Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations publication-title: Arch Neurol – volume: 27 start-page: 349 issue: 3 year: 2012 end-page: 356 article-title: Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines publication-title: Mov Disord – volume: 21 start-page: 83 issue: 2 year: 2008 end-page: 86 article-title: F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients publication-title: Cogn Behav Neurol – volume: 79 start-page: 1161 issue: 11 year: 2012 end-page: 1167 article-title: Abeta‐amyloid deposition in patients with Parkinson disease at risk for development of dementia publication-title: Neurology – volume: 19 start-page: 885 issue: 8 year: 2004 end-page: 891 article-title: Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism publication-title: Mov Disord – volume: 120 start-page: 827 issue: 6 year: 2010 end-page: 828 article-title: Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment publication-title: Acta Neuropathol – volume: 62 start-page: 1265 issue: 8 year: 2005 end-page: 1269 article-title: Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study publication-title: Arch Neurol – volume: 65 start-page: 1716 issue: 11 year: 2005 end-page: 1722 article-title: Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways publication-title: Neurology – volume: 54 start-page: 1272 issue: 6 year: 2000 end-page: 1276 article-title: APOE and the risk of PD with or without dementia in a population‐based study publication-title: Neurology – volume: 13 start-page: 394 issue: 7 year: 2007 end-page: 398 article-title: Auditory event‐related potentials in Parkinson's disease: prominent correlation with attention publication-title: Parkinsonism Relat Disord – volume: 27 start-page: 393 issue: 3 year: 2012 end-page: 399 article-title: Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course publication-title: Mov Disord – volume: 27 start-page: 945 issue: 12 year: 2006 end-page: 951 article-title: Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment publication-title: Nucl Med Commun – volume: 34 start-page: 312 issue: 5‐6 year: 2012 end-page: 318 article-title: Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease publication-title: Dement Geriatr Cogn Disord – volume: 5 start-page: 23 issue: 1 year: 1994 end-page: 28 article-title: EEG frequency analysis in demented and nondemented parkinsonian patients publication-title: Dementia – volume: 27 start-page: 727 issue: 6 year: 2012 end-page: 734 article-title: Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia publication-title: Mov Disord – volume: 83 start-page: 188 issue: 2 year: 2012 end-page: 194 article-title: Grey matter atrophy in cognitively impaired Parkinson's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 20 start-page: 339 issue: 4 year: 1993 end-page: 344 article-title: Technetium‐99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization publication-title: Eur J Nucl Med – ident: e_1_2_13_68_1 doi: 10.3389/fnhum.2015.00130 – ident: e_1_2_13_22_1 doi: 10.1016/j.parkreldis.2013.03.009 – ident: e_1_2_13_74_1 doi: 10.1371/journal.pone.0073094 – ident: e_1_2_13_244_1 doi: 10.1097/RLU.0b013e3182873511 – ident: e_1_2_13_89_1 doi: 10.1016/j.neulet.2008.10.018 – ident: e_1_2_13_236_1 doi: 10.2169/internalmedicine.44.1046 – ident: e_1_2_13_183_1 doi: 10.1148/radiol.12111280 – ident: e_1_2_13_240_1 doi: 10.1097/00006231-199213100-00007 – ident: e_1_2_13_134_1 doi: 10.1002/mds.10444 – ident: e_1_2_13_86_1 doi: 10.1006/geno.2002.6707 – ident: e_1_2_13_232_1 doi: 10.1016/j.parkreldis.2015.05.020 – ident: e_1_2_13_215_1 doi: 10.1002/ana.410400309 – volume: 7 start-page: 124 year: 2015 ident: e_1_2_13_77_1 article-title: Microglial cell dysregulation in brain aging and neurodegeneration publication-title: Front Aging Neurosci – ident: e_1_2_13_119_1 doi: 10.1016/j.neulet.2013.12.051 – ident: e_1_2_13_165_1 doi: 10.1016/j.parkreldis.2014.08.024 – ident: e_1_2_13_136_1 doi: 10.1001/archneur.62.2.281 – ident: e_1_2_13_146_1 doi: 10.1136/jnnp-2012-304126 – ident: e_1_2_13_168_1 doi: 10.3174/ajnr.A2860 – ident: e_1_2_13_221_1 doi: 10.1001/jamaneurol.2014.2757 – ident: e_1_2_13_54_1 doi: 10.1002/mds.22227 – volume: 27 start-page: 4832 issue: 18 year: 2007 ident: e_1_2_13_112_1 article-title: Catechol O‐methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0774-07.2007 – ident: e_1_2_13_155_1 doi: 10.1212/WNL.46.3.678 – ident: e_1_2_13_214_1 doi: 10.1212/WNL.0b013e3181ab2b58 – ident: e_1_2_13_235_1 doi: 10.1002/mds.20463 – ident: e_1_2_13_57_1 doi: 10.2169/internalmedicine.52.0474 – ident: e_1_2_13_217_1 doi: 10.1001/archneur.60.12.1745 – ident: e_1_2_13_241_1 doi: 10.1136/jnnp.54.9.787 – ident: e_1_2_13_10_1 doi: 10.1002/ana.20635 – ident: e_1_2_13_64_1 doi: 10.1007/s00415-012-6648-6 – ident: e_1_2_13_210_1 doi: 10.1097/WAD.0b013e31824acd84 – ident: e_1_2_13_82_1 doi: 10.1016/j.neulet.2006.12.008 – ident: e_1_2_13_108_1 doi: 10.1080/13803390903521018 – ident: e_1_2_13_139_1 doi: 10.1136/jnnp-2011-300828 – ident: e_1_2_13_226_1 doi: 10.1016/j.neuroimage.2007.09.072 – ident: e_1_2_13_102_1 doi: 10.1002/ana.10846 – ident: e_1_2_13_182_1 doi: 10.1002/mds.22007 – ident: e_1_2_13_73_1 doi: 10.1097/WNN.0b013e31817995e7 – ident: e_1_2_13_135_1 doi: 10.1212/01.WNL.0000149510.41793.50 – ident: e_1_2_13_260_1 doi: 10.2967/jnumed.111.089946 – ident: e_1_2_13_131_1 doi: 10.1016/j.parkreldis.2012.04.028 – ident: e_1_2_13_28_1 doi: 10.1016/S0140-6736(05)79387-9 – ident: e_1_2_13_121_1 doi: 10.1093/brain/awh088 – ident: e_1_2_13_35_1 doi: 10.1016/j.parkreldis.2010.10.003 – ident: e_1_2_13_286_1 doi: 10.1111/1469-8986.3720127 – ident: e_1_2_13_169_1 doi: 10.1007/s00330-013-2775-4 – ident: e_1_2_13_130_1 doi: 10.1002/mds.22799 – ident: e_1_2_13_161_1 doi: 10.1002/mds.26312 – ident: e_1_2_13_193_1 doi: 10.1159/000345537 – ident: e_1_2_13_47_1 doi: 10.1016/j.expneurol.2012.01.024 – ident: e_1_2_13_59_1 doi: 10.1016/j.parkreldis.2014.03.016 – ident: e_1_2_13_70_1 doi: 10.1002/ana.10483 – volume: 2014 start-page: 903796 year: 2014 ident: e_1_2_13_63_1 article-title: Cognitive status correlates with CXCL10/IP‐10 levels in Parkinson's disease publication-title: Parkinsons Dis – ident: e_1_2_13_234_1 doi: 10.1002/mds.26191 – ident: e_1_2_13_293_1 doi: 10.1007/BF02252920 – ident: e_1_2_13_118_1 doi: 10.1016/j.neulet.2013.02.024 – ident: e_1_2_13_224_1 doi: 10.1002/mds.25286 – ident: e_1_2_13_133_1 doi: 10.1002/mds.20371 – ident: e_1_2_13_250_1 doi: 10.1016/j.clineuro.2004.12.005 – ident: e_1_2_13_192_1 doi: 10.1097/WAD.0b013e3181611011 – ident: e_1_2_13_187_1 doi: 10.1007/s00415-014-7591-5 – ident: e_1_2_13_272_1 doi: 10.1097/WNP.0b013e31818f50de – ident: e_1_2_13_280_1 doi: 10.1016/j.jns.2011.05.034 – ident: e_1_2_13_176_1 doi: 10.3389/fneur.2013.00037 – ident: e_1_2_13_191_1 doi: 10.1001/archneur.59.9.1415 – ident: e_1_2_13_123_1 doi: 10.1212/01.WNL.0000153070.82309.D4 – ident: e_1_2_13_25_1 doi: 10.3389/fnagi.2014.00053 – ident: e_1_2_13_128_1 doi: 10.1136/jnnp-2013-305805 – ident: e_1_2_13_288_1 doi: 10.1177/089198879300600301 – ident: e_1_2_13_160_1 doi: 10.1111/j.1460-9568.2009.06892.x – ident: e_1_2_13_294_1 doi: 10.1007/BF02259661 – ident: e_1_2_13_30_1 doi: 10.1016/j.jns.2014.05.052 – ident: e_1_2_13_49_1 doi: 10.1097/FPC.0b013e32835693f7 – ident: e_1_2_13_163_1 doi: 10.1016/j.parkreldis.2014.10.014 – ident: e_1_2_13_209_1 doi: 10.1016/S0022-510X(99)00127-6 – ident: e_1_2_13_238_1 doi: 10.1111/j.1600-0404.2007.00887.x – ident: e_1_2_13_27_1 doi: 10.1001/archneurol.2012.1654 – ident: e_1_2_13_207_1 doi: 10.3389/fnsys.2014.00045 – ident: e_1_2_13_117_1 doi: 10.1016/j.neulet.2010.05.041 – ident: e_1_2_13_248_1 doi: 10.1136/jnnp.55.10.960 – ident: e_1_2_13_253_1 doi: 10.1093/brain/awu159 – ident: e_1_2_13_277_1 doi: 10.1002/acn3.129 – ident: e_1_2_13_164_1 doi: 10.1136/jnnp-2013-305062 – ident: e_1_2_13_36_1 doi: 10.1016/j.parkreldis.2015.04.027 – ident: e_1_2_13_279_1 doi: 10.3233/JPD-140480 – volume: 27 start-page: 119 issue: 1 year: 2011 ident: e_1_2_13_42_1 article-title: Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid‐beta pathway publication-title: J Alzheimers Dis doi: 10.3233/JAD-2011-110587 – ident: e_1_2_13_143_1 doi: 10.1001/archneurol.2011.725 – ident: e_1_2_13_41_1 doi: 10.1016/j.bbi.2013.07.007 – ident: e_1_2_13_188_1 doi: 10.1212/WNL.0000000000001020 – ident: e_1_2_13_227_1 doi: 10.1212/WNL.0b013e3181c7da8e – ident: e_1_2_13_255_1 doi: 10.1111/j.1468-1331.2007.01977.x – ident: e_1_2_13_201_1 doi: 10.1016/j.jns.2006.05.033 – ident: e_1_2_13_242_1 doi: 10.1177/089198879100400404 – ident: e_1_2_13_18_1 doi: 10.1002/mds.23287 – ident: e_1_2_13_251_1 doi: 10.1038/npp.2012.255 – ident: e_1_2_13_184_1 doi: 10.1159/000334765 – ident: e_1_2_13_109_1 doi: 10.1002/mds.26071 – ident: e_1_2_13_170_1 doi: 10.1177/1533317512470207 – ident: e_1_2_13_206_1 doi: 10.1002/mds.22158 – ident: e_1_2_13_147_1 doi: 10.1212/WNL.0000000000000483 – ident: e_1_2_13_185_1 doi: 10.1002/hbm.22499 – ident: e_1_2_13_87_1 doi: 10.1002/mds.20481 – ident: e_1_2_13_154_1 doi: 10.1002/hbm.21245 – ident: e_1_2_13_174_1 doi: 10.1002/hbm.22101 – ident: e_1_2_13_56_1 doi: 10.1016/j.parkreldis.2014.02.023 – year: 2014 ident: e_1_2_13_60_1 article-title: Presence and progression of non‐motor symptoms in relation to uric acid in de novo Parkinson's disease publication-title: Eur J Neurol – ident: e_1_2_13_120_1 doi: 10.1111/j.1468-1331.2009.02706.x – ident: e_1_2_13_26_1 doi: 10.1002/mds.22594 – ident: e_1_2_13_285_1 doi: 10.1007/s00702-008-0132-6 – volume: 28 start-page: 384 issue: 4 year: 2011 ident: e_1_2_13_281_1 article-title: Relationship between slowing of the EEG and cognitive impairment in Parkinson disease publication-title: J Clin Neurophysiol – ident: e_1_2_13_137_1 doi: 10.1136/jnnp.2006.093849 – ident: e_1_2_13_94_1 doi: 10.1002/mds.22357 – ident: e_1_2_13_13_1 doi: 10.1093/brain/awr031 – ident: e_1_2_13_198_1 doi: 10.1093/brain/awt337 – ident: e_1_2_13_79_1 doi: 10.1016/j.neulet.2006.07.037 – ident: e_1_2_13_62_1 doi: 10.1016/j.neulet.2009.10.062 – ident: e_1_2_13_296_1 doi: 10.1016/j.parkreldis.2006.04.008 – ident: e_1_2_13_202_1 doi: 10.1002/mds.22899 – ident: e_1_2_13_51_1 doi: 10.1001/archneur.61.6.865 – ident: e_1_2_13_111_1 doi: 10.3109/07853890.2013.849003 – ident: e_1_2_13_113_1 doi: 10.1002/mds.20118 – ident: e_1_2_13_138_1 doi: 10.1002/mds.23477 – ident: e_1_2_13_197_1 doi: 10.1093/brain/awf134 – ident: e_1_2_13_254_1 doi: 10.1016/j.parkreldis.2010.08.021 – ident: e_1_2_13_115_1 doi: 10.1002/mds.23319 – ident: e_1_2_13_125_1 doi: 10.1016/j.parkreldis.2015.06.013 – ident: e_1_2_13_229_1 doi: 10.1002/mds.25048 – ident: e_1_2_13_95_1 doi: 10.1001/archneur.62.8.1265 – ident: e_1_2_13_3_1 doi: 10.1001/archneur.60.3.387 – ident: e_1_2_13_179_1 doi: 10.3389/fnins.2014.00207 – ident: e_1_2_13_76_1 doi: 10.1016/j.neurobiolaging.2015.01.002 – ident: e_1_2_13_190_1 doi: 10.1016/j.parkreldis.2012.11.012 – ident: e_1_2_13_258_1 doi: 10.1159/000315036 – ident: e_1_2_13_9_1 doi: 10.1002/mds.24893 – ident: e_1_2_13_278_1 doi: 10.1212/WNL.0b013e318224af8d – ident: e_1_2_13_91_1 doi: 10.1016/j.jns.2006.05.032 – ident: e_1_2_13_93_1 doi: 10.1002/mds.24946 – ident: e_1_2_13_211_1 doi: 10.1007/s00401-015-1392-5 – ident: e_1_2_13_50_1 doi: 10.1016/j.archger.2013.04.015 – ident: e_1_2_13_71_1 doi: 10.1016/j.jocn.2015.02.013 – ident: e_1_2_13_20_1 doi: 10.1016/j.neulet.2010.10.015 – ident: e_1_2_13_105_1 doi: 10.1002/ajmg.b.30611 – ident: e_1_2_13_196_1 doi: 10.1093/brain/123.2.340 – ident: e_1_2_13_88_1 doi: 10.1001/archneur.64.2.261 – ident: e_1_2_13_151_1 doi: 10.1002/mds.25982 – ident: e_1_2_13_177_1 doi: 10.1016/S1474-4422(12)70138-2 – ident: e_1_2_13_204_1 doi: 10.1111/ane.12365 – ident: e_1_2_13_148_1 doi: 10.14802/jmd.11014 – ident: e_1_2_13_96_1 doi: 10.1212/WNL.54.6.1272 – volume: 36 start-page: 215 issue: 4 year: 1996 ident: e_1_2_13_295_1 article-title: Event‐related potentials in Parkinson's disease publication-title: Electromyogr Clin Neurophysiol – ident: e_1_2_13_273_1 doi: 10.1016/0013-4694(91)90134-P – ident: e_1_2_13_126_1 doi: 10.1371/journal.pone.0064222 – ident: e_1_2_13_16_1 doi: 10.1007/s00702-011-0716-4 – ident: e_1_2_13_78_1 doi: 10.1212/WNL.0b013e3181a2e8d0 – ident: e_1_2_13_46_1 doi: 10.1371/journal.pone.0048783 – ident: e_1_2_13_5_1 doi: 10.1002/mds.20974 – ident: e_1_2_13_265_1 doi: 10.1002/hbm.20033 – ident: e_1_2_13_106_1 doi: 10.1002/mds.24045 – ident: e_1_2_13_216_1 doi: 10.1212/01.wnl.0000191154.78131.f6 – ident: e_1_2_13_152_1 doi: 10.1002/mds.22858 – ident: e_1_2_13_38_1 doi: 10.1186/alzrt255 – ident: e_1_2_13_80_1 doi: 10.1111/j.1600-0404.2005.00535.x – ident: e_1_2_13_52_1 doi: 10.1002/mds.22522 – ident: e_1_2_13_67_1 doi: 10.1159/000371510 – ident: e_1_2_13_189_1 doi: 10.3233/JAD-132684 – ident: e_1_2_13_228_1 doi: 10.1212/WNL.0b013e31829e6f94 – ident: e_1_2_13_48_1 doi: 10.1001/jamaneurol.2015.1449 – ident: e_1_2_13_122_1 doi: 10.1371/journal.pone.0054980 – ident: e_1_2_13_65_1 doi: 10.1002/ana.22271 – ident: e_1_2_13_298_1 doi: 10.1002/mds.25040 – ident: e_1_2_13_156_1 doi: 10.1136/jnnp.2003.031237 – ident: e_1_2_13_153_1 doi: 10.1093/brain/awv211 – ident: e_1_2_13_8_1 doi: 10.1212/WNL.0b013e31829c5c86 – ident: e_1_2_13_219_1 doi: 10.1001/archgenpsychiatry.2009.106 – ident: e_1_2_13_110_1 doi: 10.1093/brain/aws318 – ident: e_1_2_13_21_1 doi: 10.1016/j.nbd.2008.12.008 – volume: 4 start-page: 677 issue: 4 year: 2014 ident: e_1_2_13_6_1 article-title: Longitudinal assessment of the pattern of cognitive decline in non‐demented patients with advanced Parkinson's Disease publication-title: J Parkinsons Dis doi: 10.3233/JPD-140398 – volume: 22 start-page: 446 issue: 3 year: 2010 ident: e_1_2_13_268_1 article-title: Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment publication-title: Psychiatr Danub – ident: e_1_2_13_269_1 doi: 10.1111/j.1600-0404.1988.tb03609.x – ident: e_1_2_13_150_1 doi: 10.1111/ene.12785 – ident: e_1_2_13_257_1 doi: 10.1002/mds.22444 – ident: e_1_2_13_186_1 doi: 10.1002/hbm.22822 – ident: e_1_2_13_223_1 doi: 10.1136/jnnp.2007.127878 – ident: e_1_2_13_132_1 doi: 10.1159/000153432 – ident: e_1_2_13_129_1 doi: 10.1016/j.jns.2014.09.049 – ident: e_1_2_13_284_1 doi: 10.1016/j.clinph.2006.06.720 – ident: e_1_2_13_44_1 doi: 10.1007/BF02260965 – ident: e_1_2_13_175_1 doi: 10.1002/hbm.22256 – ident: e_1_2_13_213_1 doi: 10.1212/WNL.0b013e3181d55f61 – ident: e_1_2_13_180_1 doi: 10.1523/JNEUROSCI.23-15-06351.2003 – ident: e_1_2_13_243_1 doi: 10.1159/000084551 – ident: e_1_2_13_83_1 doi: 10.1016/j.parkreldis.2014.02.001 – ident: e_1_2_13_158_1 doi: 10.1002/mds.25633 – ident: e_1_2_13_100_1 doi: 10.1016/j.neurobiolaging.2014.12.006 – ident: e_1_2_13_271_1 doi: 10.1093/brain/awm322 – ident: e_1_2_13_85_1 doi: 10.1002/ana.410370215 – ident: e_1_2_13_19_1 doi: 10.1007/s00415-014-7560-z – ident: e_1_2_13_23_1 doi: 10.1212/WNL.0b013e3181f39a78 – ident: e_1_2_13_61_1 doi: 10.1016/S0033-3182(10)70739-8 – ident: e_1_2_13_39_1 doi: 10.1016/j.ajpath.2013.12.007 – ident: e_1_2_13_142_1 doi: 10.1111/j.1468-1331.2010.02980.x – ident: e_1_2_13_17_1 doi: 10.1159/000094871 – ident: e_1_2_13_99_1 doi: 10.1002/ana.21192 – ident: e_1_2_13_282_1 doi: 10.1159/000370110 – ident: e_1_2_13_37_1 doi: 10.1371/journal.pone.0053250 – ident: e_1_2_13_31_1 doi: 10.1371/journal.pone.0048042 – ident: e_1_2_13_266_1 doi: 10.1136/jnnp.74.4.419 – ident: e_1_2_13_239_1 doi: 10.1007/BF00169811 – ident: e_1_2_13_90_1 doi: 10.1177/0891988709332945 – ident: e_1_2_13_166_1 doi: 10.1016/j.pscychresns.2012.06.001 – ident: e_1_2_13_249_1 doi: 10.1007/s100720170039 – ident: e_1_2_13_283_1 doi: 10.1097/WNP.0b013e3181dd4fdb – ident: e_1_2_13_274_1 doi: 10.1016/j.clinph.2013.05.001 – ident: e_1_2_13_256_1 doi: 10.1212/01.wnl.0000304050.05332.9c – ident: e_1_2_13_264_1 doi: 10.1016/j.neuroimage.2004.01.030 – ident: e_1_2_13_58_1 doi: 10.1016/j.parkreldis.2007.11.001 – ident: e_1_2_13_72_1 doi: 10.1016/S0021-9150(99)00257-9 – volume: 5 start-page: 23 issue: 1 year: 1994 ident: e_1_2_13_270_1 article-title: EEG frequency analysis in demented and nondemented parkinsonian patients publication-title: Dementia – volume: 45 start-page: 667 issue: 3 year: 1991 ident: e_1_2_13_287_1 article-title: Event‐related potentials in senile dementia of Alzheimer's type, multiinfarct dementia and Parkinson's disease publication-title: Jpn J Psychiatry Neurol – ident: e_1_2_13_195_1 doi: 10.1002/mds.25104 – ident: e_1_2_13_275_1 doi: 10.1016/S1353-8020(99)00009-7 – ident: e_1_2_13_75_1 doi: 10.4161/19420889.2014.993266 – ident: e_1_2_13_145_1 doi: 10.1177/0284185113476029 – ident: e_1_2_13_4_1 doi: 10.1002/mds.23823 – ident: e_1_2_13_199_1 doi: 10.1016/j.parkreldis.2014.07.008 – ident: e_1_2_13_98_1 doi: 10.1093/brain/awp245 – volume: 19 start-page: 937 issue: 3 year: 2010 ident: e_1_2_13_43_1 article-title: The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease publication-title: J Alzheimers Dis doi: 10.3233/JAD-2010-1289 – ident: e_1_2_13_84_1 doi: 10.1001/jamaneurol.2014.1455 – ident: e_1_2_13_292_1 doi: 10.1159/000017212 – ident: e_1_2_13_97_1 doi: 10.1001/archneurol.2011.17 – ident: e_1_2_13_290_1 doi: 10.1159/000213538 – ident: e_1_2_13_252_1 doi: 10.1007/s00259-012-2198-5 – ident: e_1_2_13_24_1 doi: 10.1016/j.parkreldis.2014.12.027 – ident: e_1_2_13_200_1 doi: 10.1002/ana.24323 – ident: e_1_2_13_212_1 doi: 10.1002/mds.20700 – ident: e_1_2_13_11_1 doi: 10.1097/WAD.0b013e31819c5ef4 – ident: e_1_2_13_7_1 doi: 10.1001/jamaneurol.2013.2110 – ident: e_1_2_13_159_1 doi: 10.1016/j.parkreldis.2008.05.002 – ident: e_1_2_13_32_1 doi: 10.1002/mds.25282 – ident: e_1_2_13_53_1 doi: 10.1097/01.WNF.0000236763.16032.60 – ident: e_1_2_13_140_1 doi: 10.1002/mds.24938 – ident: e_1_2_13_276_1 doi: 10.1016/j.parkreldis.2007.01.003 – ident: e_1_2_13_247_1 doi: 10.1016/j.parkreldis.2006.10.005 – ident: e_1_2_13_103_1 doi: 10.1016/j.jns.2011.07.047 – ident: e_1_2_13_2_1 doi: 10.1002/mds.21956 – ident: e_1_2_13_149_1 doi: 10.1002/mds.25541 – ident: e_1_2_13_181_1 doi: 10.1136/jnnp-2013-305277 – ident: e_1_2_13_205_1 doi: 10.1016/S0304-3940(01)02124-3 – ident: e_1_2_13_167_1 doi: 10.1212/WNL.0b013e3182929f62 – ident: e_1_2_13_33_1 doi: 10.1186/1471-2377-14-113 – ident: e_1_2_13_218_1 doi: 10.1007/s00415-005-0971-0 – ident: e_1_2_13_172_1 doi: 10.1002/hbm.22302 – ident: e_1_2_13_104_1 doi: 10.1016/j.parkreldis.2013.11.008 – ident: e_1_2_13_222_1 doi: 10.1111/ane.12259 – ident: e_1_2_13_69_1 doi: 10.1002/mds.870090115 – ident: e_1_2_13_233_1 doi: 10.1002/ana.23659 – ident: e_1_2_13_14_1 doi: 10.1002/mds.25857 – ident: e_1_2_13_178_1 doi: 10.1016/j.neurobiolaging.2013.06.025 – ident: e_1_2_13_107_1 doi: 10.1212/WNL.0b013e318253d54b – ident: e_1_2_13_15_1 doi: 10.1007/s00401-010-0744-4 – ident: e_1_2_13_237_1 doi: 10.1097/01.mnm.0000243370.18883.62 – ident: e_1_2_13_101_1 doi: 10.1002/mds.22682 – volume: 3 start-page: 69 issue: 1 year: 2013 ident: e_1_2_13_144_1 article-title: Mapping cortical atrophy in Parkinson's disease patients with dementia publication-title: J Parkinsons Dis doi: 10.3233/JPD-120151 – ident: e_1_2_13_291_1 doi: 10.1016/j.parkreldis.2006.12.012 – ident: e_1_2_13_40_1 doi: 10.1016/j.neurobiolaging.2014.07.043 – ident: e_1_2_13_81_1 doi: 10.1002/mds.20663 – ident: e_1_2_13_245_1 doi: 10.1002/mds.22381 – ident: e_1_2_13_171_1 doi: 10.1111/j.1600-0404.2007.00838.x – ident: e_1_2_13_220_1 doi: 10.1038/jcbfm.2012.60 – ident: e_1_2_13_299_1 doi: 10.1002/mds.25360 – ident: e_1_2_13_45_1 doi: 10.1093/brain/awp263 – ident: e_1_2_13_157_1 doi: 10.1007/s00234-004-1257-4 – ident: e_1_2_13_173_1 doi: 10.1016/j.ejrad.2015.04.014 – ident: e_1_2_13_208_1 doi: 10.1007/s00259-005-1830-z – ident: e_1_2_13_29_1 doi: 10.1016/j.biopsych.2008.02.016 – ident: e_1_2_13_116_1 doi: 10.1093/brain/awu201 – ident: e_1_2_13_262_1 doi: 10.1016/j.neuroimage.2006.09.003 – ident: e_1_2_13_124_1 doi: 10.1016/j.neurobiolaging.2010.11.015 – ident: e_1_2_13_66_1 doi: 10.1111/ene.12137 – ident: e_1_2_13_297_1 doi: 10.1016/j.neuropsychologia.2004.08.010 – ident: e_1_2_13_34_1 doi: 10.1136/jnnp.2009.199950 – ident: e_1_2_13_92_1 doi: 10.1007/s00415-009-0119-8 – ident: e_1_2_13_289_1 doi: 10.1016/0022-510X(94)90342-5 – volume: 3 start-page: 547 issue: 4 year: 2013 ident: e_1_2_13_55_1 article-title: Memory, mood, and vitamin d in persons with Parkinson's disease publication-title: J Parkinsons Dis doi: 10.3233/JPD-130206 – ident: e_1_2_13_114_1 doi: 10.1093/brain/awm313 – ident: e_1_2_13_231_1 doi: 10.1212/WNL.0b013e31827b1a07 – ident: e_1_2_13_162_1 doi: 10.1007/s00429-014-0785-x – ident: e_1_2_13_230_1 doi: 10.1002/mds.23393 – ident: e_1_2_13_261_1 doi: 10.1371/journal.pone.0110547 – ident: e_1_2_13_259_1 doi: 10.1212/WNL.0b013e3182315259 – ident: e_1_2_13_12_1 doi: 10.1212/01.WNL.0000158422.41380.82 – ident: e_1_2_13_141_1 doi: 10.1007/s00415-008-0885-8 – ident: e_1_2_13_267_1 doi: 10.1007/s00259-009-1168-z – ident: e_1_2_13_127_1 doi: 10.1016/j.parkreldis.2008.03.005 – ident: e_1_2_13_225_1 doi: 10.1212/WNL.0b013e3182698d4a – ident: e_1_2_13_263_1 doi: 10.1159/000345987 – ident: e_1_2_13_246_1 doi: 10.1159/000357128 – ident: e_1_2_13_203_1 doi: 10.1002/mds.26051 – ident: e_1_2_13_194_1 doi: 10.1016/j.neulet.2003.09.076 |
| SSID | ssj0011516 |
| Score | 2.5419805 |
| SecondaryResourceType | review_article |
| Snippet | ABSTRACT
Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease... Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 861 |
| SubjectTerms | Biomarkers Cognitive Dysfunction - blood Cognitive Dysfunction - cerebrospinal fluid Cognitive Dysfunction - diagnostic imaging Cognitive Dysfunction - etiology dementia Dementia - blood Dementia - cerebrospinal fluid Dementia - diagnostic imaging Dementia - etiology Humans mild cognitive impairment Movement disorders Parkinson Disease - blood Parkinson Disease - cerebrospinal fluid Parkinson Disease - complications Parkinson Disease - diagnostic imaging Parkinson's disease |
| Title | Biomarkers for dementia and mild cognitive impairment in Parkinson's disease |
| URI | https://api.istex.fr/ark:/67375/WNG-XCPL4PS5-P/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.26662 https://www.ncbi.nlm.nih.gov/pubmed/27193487 https://www.proquest.com/docview/1792699617 https://www.proquest.com/docview/1793569104 https://www.proquest.com/docview/1808713487 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEB5CAiUv6Zlk07SopTR58a4ty5KXPrVJ01CyYclB9qEgrMNgmvWG9S6E_vqO5KOkJKH0zaCxsY6Z-Uaa-QTwwShLtU3jgFnuAhTBgpRHUYDOL2R6yHjqN_RHp_z4kn2fJJMV-NTWwtT8EN2Gm9MMb6-dgmeqGvwhDZ2aqo_exdvfKOaON__wrKOOQqDjrz1FJUp8hXDLKhTSQffmHV-05ob19j6geRe3esdz9BR-tL9c55v87C8Xqq9__cXm-J99egYbDSAln-sV9BxWbPkCnoyaI_eXcPKlmE1dDs-8IghwifH7iUVGstKQaXFtSJeBRFzJZTF37aQoiSuo9rVlexVpzoFeweXR14uD46C5giHQCU1o4ApfrcjT0CCStEOaD0XIM6VNrEKDxkKlsTUJVxoDrzw02ghNEXA6ykON4IPFm7Bazkq7DYRpPhRaYcCkBAaVDplisJZbletIM0F7sN9OhtQNP7m7JuNa1szKVOLoSD86PXjfid7UpBz3CX30M9pJYKddFptI5NXpNzk5GJ-w8Xkixz3YbadcNgpcSbRTlGMsGIkevOuaUfXceUpW2tnSy8QJR7zFHpFJw9SV66b4na16OXU_RAWiZ9-y7xfFw32Ro8Nz_7Dz76KvYR3BHa_T2nZhdTFf2jcIoBbqrdeU3-d2EyI |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3raxNBEB9KC-qX-tZo1VVE--XSy97e7gX8otUaNQnBtpgvsmQfB0ebi-QB4l_vzN5DKlXEbwc7d9w-ZuY3uzO_BXjujOfWZ0kkvKQARYkok71ehM4vFrYvZBY29EdjOTgVH6fpdAteNbUwFT9Eu-FGmhHsNSk4bUgf_GINnbtVF90LGeAdgUAjHNJ-bsmjEOqEi09RjdJQI9zwCsX8oH31gjfaoYH9fhnUvIhcg-s5ug5fm5-uMk7Oupu16dofv_E5_m-vbsBujUnZ62oR3YQtX96CK6P61P02DN8Uizml8SxXDDEuc2FLsZixWenYvDh3rE1CYlR1WSypnRUlo5rqUF72csXqo6A7cHr07uRwENW3MEQ25SmPqPbVqzyLHYJJ3-d5X8VyZqxLTOzQXpgs8S6VxmLslcfOOmU5Yk5iPbSIP0RyF7bLRenvAxNW9pU1GDMZhXElgVOM13JvctuzQvEO7DezoW1NUU43ZZzrilyZaxwdHUanA89a0W8VL8dlQi_ClLYS2GlKZFOp_jJ-r6eHk6GYHKd60oG9Zs51rcMrjaaKSwwHe6oDT9tm1D46UpmVfrEJMkkqEXKJv8hkcUYVuxl-5161ntof4goBdGjZD6viz33Ro7fH4eHBv4s-gauDk9FQDz-MPz2Ea4j1ZJXltgfb6-XGP0I8tTaPg9r8BBd4F0A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZaxRBEC5CAsEX72M1aiuieZnNbE9P9yw-aeIadXdZjCH7IDTbx8BgdjbsAeKvt6rnkEgU8W2ga4bpo6q-6q76GuCFM55bnyWR8JICFCWiTPZ6ETq_WNi-kFnY0B-N5fGp-DhNp1vwuqmFqfgh2g030oxgr0nBL1x-8Is0dO5WXfQuZH93hERPRojoc8sdhUgn3HuKWpSGEuGGVijmB-2rl5zRDo3r96uQ5mXgGjzP4AZ8bf65Sjj51t2sTdf--I3O8T87dROu14iUvamW0C3Y8uVt2B3VZ-53YPi2WMwpiWe5YohwmQsbisWMzUrH5sW5Y20KEqOay2JJ7awoGVVUh-KyVytWHwTdhdPBuy-Hx1F9B0NkU57yiCpfvcqz2CGU9H2e91UsZ8a6xMQOrYXJEu9SaSxGXnnsrFOWI-IkzkOL6EMk92C7XJT-ATBhZV9ZgxGTURhVEjTFaC33Jrc9KxTvwH4zGdrWBOV0T8a5rqiVucbR0WF0OvC8Fb2oWDmuEnoZZrSVwE5TGptK9dn4vZ4eToZicpLqSQf2minXtQavNBoqLjEY7KkOPGubUffoQGVW-sUmyCSpRMAl_iKTxRnV62b4nfvVcmp_iCuEz6FlPyyKP_dFj45OwsPDfxd9CruTo4Eefhh_egTXEOjJKsVtD7bXy41_jGBqbZ4EpfkJvPwV7w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biomarkers+for+dementia+and+mild+cognitive+impairment+in+Parkinson%27s+disease&rft.jtitle=Movement+disorders&rft.au=Delgado%E2%80%90Alvarado%2C+Manuel&rft.au=Gago%2C+Bel%C3%A9n&rft.au=Navalpotro%E2%80%90Gomez%2C+Irene&rft.au=Jim%C3%A9nez%E2%80%90Urbieta%2C+Haritz&rft.date=2016-06-01&rft.issn=0885-3185&rft.eissn=1531-8257&rft.volume=31&rft.issue=6&rft.spage=861&rft.epage=881&rft_id=info:doi/10.1002%2Fmds.26662&rft.externalDBID=10.1002%252Fmds.26662&rft.externalDocID=MDS26662 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |